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Abstract
Nearly half of all youths experience a mental health disorder at some point during
childhood (Merikangas et al., 2010). Pediatric psychopathology is associated with a substantial
amount of impairment in the school, social, and home domains, and such symptoms can have
adverse impacts on subsequent development (Beauchaine & Hinshaw, 2013; Patel, Flisher,
Hetrick, & McGorry, 2007). Fortunately, a number of medications have demonstrated efficacy in
treating a number of mental health conditions (Martin, Scahill, & Kratochvil, 2010). Despite
these demonstrated effects, treatment response is often incomplete, and the mechanisms by
which pharmacotherapy lead to behavior change are not well understood. However, research in
pediatric psychopharmacology has often not considered the role of psychosocial variables,
despite their promise to explain much variance in psychiatric outcomes and the robust influence
they have demonstrated in psychotherapy-based behavior change (e.g., Shirk & Karver, 2011).
This study investigated the role of four psychosocial variables in treatment outcome in pediatric
psychiatric practice: medication adherence, therapeutic alliance, motivation for behavior change,
and expectancies for positive treatment outcome. Surprising patterns of effects were found, with
psychosocial variables being associated with both decreases and increases in symptomology
depending on the circumstance (e.g., externalizing behavior), and many inconsistencies were
observed among these patterns. While psychosocial variables are often portrayed as having
uniformly positive impacts on treatment, their role in pediatric psychiatry may not be as
straightforward as is commonly depicted in other diseases and therapeutic approaches. In
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particular, the nature of their effects on outcome may vary across symptom presentations and
intervention approaches. Based on these findings, recommendations for clinical practice and
future research are discussed which affect all patients, researchers, and medical providers who
participate in pediatric psychiatric treatment.

vi

Introduction
Psychiatric disorders in children are associated with devastating individual consequences
and present an enormous public health burden. During childhood, 49.5% of youth experience a
mental disorder at some point, and 22.2% of children experience symptoms that are
characterized by severe impairment and/or distress (Merikangas et al., 2010). By adolescence,
nearly two million American children perceive more than half of their days as “mentally
unhealthy” (Perou et al., 2013). Pediatric psychopathology is also associated with impaired
performance in the school, social, and home environments, and can lead to family disruption and
even suicide (Beauchaine & Hinshaw, 2013). Such impairment is compounded longitudinally, as
a majority of adults with mental disorders experience onset of symptoms during youth that
continue to persist into adulthood (Kessler et al., 2005). This adversely affects the achievement
of developmental milestones, including academic, vocational, and social goals (Patel, Flisher,
Hetrick, & McGorry, 2007). These behavioral difficulties can also affect other health
functioning; for instance, youth with mental disorders are at a higher risk of contracting HIV
relative to peers without any mental disorders (Donenberg, 2005; Donenberg, Emerson, Bryant,
Wilson, & Weber-Shifrin, 2001). On a broader level, the associated costs of mental illness in
young people are staggering, as annual costs associated with pediatric mental illness are
estimated at $247 billion dollars (Perou et al., 2013), and mental disorders are the costliest health
condition to treat in children (Soni, 2009). As a whole, mental health problems in children are
widespread, debilitating, and have detrimental effects on families, communities, and society.
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To address pediatric mental illness, two major approaches have been psychotherapy and
medication treatment (Olfson, He, & Merikangas, 2013; Olfson & Marcus, 2010). While both
modalities have displayed efficacy for a number of conditions (Kendall, 2011; Martin, Scahill, &
Kratochvil, 2010), psychopharmacological interventions are used over five times more
frequently than psychotherapy for youths (Olfson, Blanco, Wang, Laje, & Correll, 2014), and an
estimated 14.2% of adolescents report taking a psychotropic medication in the preceding 12
months (Merikangas, He, Rapoport, Vitiello, & Olfson, 2013). Medication use is also expanding
over time, as the number of physician visits resulting in psychotropic medication prescriptions
has more than doubled during the 15 year period prior to 2010 (Olfson, et al., 2014). However,
the potential of side effects and adverse developmental impacts of medication use has led to
some concern, especially given the extensive usage of pharmacotherapy in children. Also, while
pharmacotherapy is frequently efficacious, real world treatment response is often incomplete
(e.g., Franklin et al., 2011; The TADS Team, 2007; Walkup et al., 2008). Given that the
development of new psychotropic agents has slowed greatly relative to the rest of medicine
(Cowen, 2011), new “miracle drugs” to improve psychiatric outcomes are not on the
developmental horizon.
Given this context, what can be done to improve the real world effectiveness and safety
of contemporary pharmacotherapy? Many efforts to address these concerns have manifested
through the development of new pharmacological agents, which rely on an assumption that the
mechanism of change in pharmacotherapy is largely biological. Unfortunately, this approach to
pediatric psychopharmacology has led to limited improvements in patient outcomes in the past
several decades. While some progress has been made in reducing side effects, newer
pharmacological agents have not produced drastic improvements in patient outcomes (e.g.,
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Lieberman et al., 2005). As it currently stands, purely biological approaches to psychiatry have
not produced fully optimal outcomes, and millions of children are not obtaining optimal
symptom relief as a result. In addition, these suboptimal individual-level outcomes can aggregate
into a large scale attenuation of therapeutic effects, leading to additional burden on the overall
healthcare system when patients remain in active treatment for excessively long periods.
However, a different approach is to directly incorporate psychosocial variables in
pharmacotherapy approaches, which have demonstrated substantial impact on outcomes in
psychotherapy and conventional medicine (e.g., Hall, Ferreira, Maher, Latimer, & Ferreira,
2010; Osborn & Egede; Shirk, Karver, & Brown, 2011). These variables are known as “common
factors” in the psychotherapy literature, as they have been highlighted for their importance across
all methods of psychotherapy for over 70 years (Rosenzweig, 1936), but in the context of
pharmacological interventions they have been characterized more frequently in terms of nuisance
confounds and “placebo effects” (Miller, Colloca, & Kaptchuk, 2009). However, while
psychosocial variables have often been considered to be research confounds, perhaps instead
they can be construed as novel mechanisms to capitalize upon in order to provide new avenues
for outcome improvement. At present, quantitative data to justify the roles of such variables are
limited in pediatric psychiatry, but common factors are active in some capacity during all mental
health treatment, including psychiatry (Patterson, 1985; Verhulst, Kramer, Swann, Hale-Richlen,
& Beahrs, 2013). These psychosocial variables are also likely to work in tandem with biological
treatments, as placebo effects have a variety of neuroendocrine consequences (e.g., modulation
of neurotransmitter and hormonal functioning, changes in brain-based metabolism; Finniss,
Kaptchuk, Miller, & Benedetti, 2010). To artificially dichotomize such effects as separate from
biology results in imprecision in modeling the effects of pharmacotherapy for youth.
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Among psychosocial variables, one factor that has received relatively little attention in
pediatric psychiatry has been medication adherence, despite adherence rates being remarkably
poor for a number of widely used medications (Brown & Bussell, 2011; Fischer et al., 2010).
Another series of variables that have received limited empirical examination in pediatric
psychiatry include the therapeutic alliance, motivation for behavior change, and expectancies for
positive treatment outcome. These variables are readily available for modification and do not
depend on hypothetical scientific developments in order to bring about improved patient
outcomes. At present, patient adherence, therapeutic alliance, and patient expectancies and
motivation remain understudied as active ingredients in pediatric psychiatry, as biological
interventions are often construed as the integral active components. However, increasing the
understanding of psychosocial variables in pediatric psychiatry could provide a foundation for
innovative approaches that aim to improve care for a large number of patients. A review of
relevant psychosocial variables follows.
Considering the Role of Adherence in Pediatric Psychiatry
Adherence refers to the extent that patients follow a prescribed medication regimen, and
is critical to ensure the effectiveness of interventions (Osterberg & Blaschke, 2005). Indeed,
billions of dollars in drug development are rendered ineffectual if patients do not take their
medications as prescribed. In child psychiatry, adherence has often been observed to be poor,
and adherence rates have been reported to be under 50% for commonly used medications such as
serotonin reuptake inhibitors (frequently used for depression and anxiety) and stimulants
(frequently used for attention-deficit/hyperactivity disorder, i.e., ADHD; Gau et al., 2006;
Murray, de Vries, & Wong, 2004; Richardson, DiGiuseppe, Christakis, McCauley, & Katon,
2004). While data on the adherence-outcome relationship are limited in pediatric

4

psychopharmacology, nonadherence to sertraline has been associated with a nearly 30%
reduction in response rates in adult depression (von Knorring, Åkerblad, Bengtsson, Carlsson, &
Ekselius, 2006). Psychiatric medication nonadherence is also a major contributor to drug-related
emergency hospital admissions (Procyshyn, Barr, Brickell, & Honer, 2010), and poor medication
adherence has been associated with increased rates of relapse and hospital readmission in
patients with schizophrenia and bipolar disorder (Velligan et al., 2009). Conversely,
improvements in adherence predict improved outcomes in treatment for pediatric ADHD and
depression (Pappadopulos et al., 2009; Woldu et al., 2011). These adherence-outcome
relationships are also seen in other fields of medicine, as meta-analytic estimates indicate that the
difference between low and high adherence makes for a 26% difference in desired medical
outcomes, and variability in adherence can compromise medical outcomes as much as 71%
(DiMatteo, Giordani, Lepper, & Croghan, 2002). Poor adherence is not restricted to psychiatry
and remains a common problem in a variety of chronic health conditions in youth, including
diabetes, renal disease, and AIDS (DiMatteo, 2004). Inadequate adherence is also costly in terms
of financial expenditures. Increases in costs ranging from $750 to $2,000 have been observed for
each nonadhering patient in adult antidepressant treatment (Revicki, Simon, Chan, Katon, &
Heiligenstein, 1998; Thompson, Peveler, Stephenson, & McKendrick, 2000), and costs
associated with vocational absenteeism due to antidepressant noncompliance are over $1,000
annually per nonadherent patient (Birnbaum et al., 2010). In contrast, adequate adherence to
antidepressants has been associated with a reduction in overall medical costs (Cantrell, Eaddy,
Shah, Regan, & Sokol, 2006).
Adherence stands to be an important mechanism of outcome in pediatric psychiatry,
especially given the frequent usage of psychiatric medications in youth along with low observed
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adherence rates. As it stands already, unsuccessful treatment as a result of nonadherence burdens
an already overtaxed mental health care system. Thus, increasing understanding of how children
adhere to psychiatric medications can help individual patients, reduce financial costs to the
medical system, and allow the mental health system to treat the millions of youths in need more
effectively. Despite these wide ranging consequences, medication adherence in pediatric
psychiatry remains an understudied variable (McGuinness & Worley, 2010).
In considering variables that have traditionally affected adherence, a number of factors
have emerged. With regard to physical factors, side effects of medication as well as convenience
of administration predict adherence (Julius, Novitsky, & Dubin, 2009; Mitchell, 2006).
Exemplars of these phenomena include patients who may find it easier to adhere to once-a-day
medication dosing relative to multiple intradaily doses, and patients who experience greater side
effects can sometimes reduce the amount of medication they are taking when they experience
these undesired effects. Demographic factors also have relationships with adherence. Overall
adherence is worse for children relative to adults (Costello, Wong, & Nunn, 2004) and in
particular adolescents can show increased difficulties with adherence (Matsui, 2007).
In addition to these factors, one unique aspect of adherence in pediatric psychiatry is that
the pathology itself can reduce adherence (Smith & Shuchman, 2005). This is particularly
impactful for child psychiatry, as a recursive process can exist where adherence to psychiatric
intervention is reduced by psychopathology, and then this low adherence precludes
improvements in psychopathology, which subsequently continues to impact adherence. For
example, a depressed child may be less likely to be motivated to take medication, adhere more
poorly, and remain more depressed as a product of this nonadherence, which subsequently
continues to attenuate adherence as part of a vicious cycle.
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Although physical, demographic, and psychopathology-related factors can affect
adherence, they are not fully predictive of behavior, and at times provide only limited avenues
for adherence improvement. However, other psychosocial variables provide a potential
opportunity to improve adherence and merit further consideration, especially as significant
variability has been observed among physicians with regard to their approaches to adherence
(Drotar, 2009). One traditional approach has been defined as the health beliefs model, which
focuses on the perceived benefits of medications in contrast to perceived harms (Rosenstock,
1966). A related framework that has also been applied to adherence behavior is social cognitive
theory, which focuses on expectations for positive outcomes and expectations for ability to
complete adherence behavior (Bandura, 1998). Such approaches have been successful for
increasing adherence and health-promoting behavior in a number of medical conditions,
including asthma and heart disease (Bandura, 2004). Yet another approach to psychosocial
variables in adherence has been the theory of planned behavior (TPB), which focuses on three
components: patient attitudes towards adherence, patients’ perceived subjective norms towards
adherence, and patient expectations about their ability to engage in adherence (Ajzen, 2011). The
TPB model predicts engagement for a number of health behaviors, ranging from increases in
exercise to reductions in risk-taking behavior (McEachan, Conner, Taylor, & Lawton, 2011).
However, these traditional models suffer from some shortcomings. They were originally
conceptualized in adults, and the complexity of these models is compounded in pediatric care as
these variables can apply to both parents and children (Matsui, 2007). Also, while these
traditional approaches have made some inroads into predicting adherence, much variance
remains to be explained (Riekert, Ockene, & Pbert, 2013). They are further limited by their focus
on patient-level behavior, neglecting patient-provider and family-based interactions (Clark &
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Janevic, 2013). To address this limitation, models that incorporate the patient-provider
interaction (such as therapeutic alliance) merit addressing in the context of adherence and
outcome (Diamond, 2012).
Considering the Role of Therapeutic Alliance in Pediatric Psychiatry
The therapeutic alliance focuses on the interaction between patient and clinician, and in
adults has been conceptualized in terms of three components: the bond between clinician and
patient, agreement on the tasks to be completed in therapy, and agreement on the therapeutic
goals to be achieved (Bordin, 1979). In children, these individual components have been
identified as important, but at times have not emerged as separate factors, and instead a onefactor model of alliance has been primarily found (Shirk, et al., 2011). Differences between adult
and pediatric alliance models have arisen for a number of reasons, including distinct perspectives
provided by children and the presence of multiple parties in therapy (e.g., parents and children;
Zack, Castonguay, & Boswell, 2007). Children may also not have the cognitive capacity to
differentiate task and goals (which are more cognitively based) from the bond (which is more
emotionally based; Shirk & Karver, 2011). With regard to the process of alliance in child
therapy, alliance formation involves the clinician simultaneously serving in a position of active
listening while also providing a directive framework for treatment (Shirk, et al., 2011).
The alliance has been highlighted most extensively in the psychotherapy literature, where
it has shown a robust effect on treatment outcome across psychotherapies (Horvath, Del Re,
Flückiger, & Symonds, 2011). Additionally, alliance can predict other important child therapy
processes such as patient engagement and retention (Castro-Blanco & Karver, 2010; Garcia &
Weisz, 2002). However, while the necessity of the physician-patient relationship has been
identified as critical in adherence for overall pediatric practice (Winnick, Lucas, Hartman, &
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Toll, 2005), it has received very little attention in child psychiatry despite the patient-provider
relationship being central to establishing a diagnosis and to making a treatment prescription.
Nevertheless, some empirical data has addressed the alliance in psychiatry. In adult
depression, the average alliance throughout treatment accounts for 19% to 56% of variance in
pharmacological treatment outcome (Krupnick et al., 1996; Weiss, Gaston, Propst, Wisebord, &
Zicherman, 1997), and alliance can predict outcomes even when already accounting for
technique effects from cognitive behavioral therapy (CBT) and/or antidepressant medication
(Klein et al., 2003). Early alliance in treatment may be particularly predictive of antidepressant
outcomes (Blatt & Zuroff, 2005). Alliance may also have a specific effect on medication
outcome, as it has displayed differential effects between active compounds and placebo
medication in SSRI treatment for depression (Strunk et al., 2010). Alliance and expectancies
have also predicted adherence and outcome in pharmacotherapy for bipolar disorder (Gaudiano
& Miller, 2006; Sylvia et al., 2013; Zeber et al., 2008) and in the usage of antipsychotic
medication (Frank & Gunderson, 1990; McCabe et al., 2012). Alliance may affect other therapy
process variables as well, as the odds of medical treatment adherence are 2.16 times greater
overall if a physician is a good communicator (Zolnierek & DiMatteo, 2009). Thus, these limited
data indicate that alliance is not only an accessory to psychiatric treatment, but may in fact drive
a significant proportion the treatment process and subsequent outcome in pharmacotherapy.
A number of reasons have been posited regarding why alliance may affect outcomes. One
theory focuses on the sufficiency of strong alliance formation, which allows the patient to enact
changes that might not otherwise be made alone (Norcross, 2010). In this context, the alliance is
the principal stimulus that leads patients to identify and enact positive change as a result of
therapy. Another aspect is that alliance helps patients engage in other therapy elements (De
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Nadai, King, Karver, & Storch, 2014). Under this conceptualization, a strong alliance provides a
foundation for communication in therapy that enhances patient engagement in specific
techniques and interventions provided by the clinician, which then result in therapeutic change.
Alliance has been found to be consistently related to adherence in a number of mental health
treatments, and may work partially through improving expectancies for treatment (Thompson &
McCabe, 2012). In psychiatry, it has been suggested that alliance can directly improve patient
outcomes, and may also indirectly improve outcomes through its positive effects on adherence
(Priebe & McCabe, 2008). However, this hypothesis remains understudied. No comparative data
exist for children, though doctor-patient communication (an analogue of alliance) has been
shown to predict adherence to a variety of pediatric medical treatments (DiMatteo, 2004). Child
psychiatry also differs from traditional therapy with adults due to the dual importance of both
child-clinician as well as parent-clinician alliance (Joshi, 2006), as child and parent alliance may
have some orthogonal contributions to mental health outcomes (Bickman et al., 2012; Hawley &
Weisz, 2005). While understudied, alliance affects both process and outcome variables in
psychological and medical treatments.
Considering the Role of Motivation for Behavior Change in Pediatric Psychiatry
While patient motivation has been identified as a key principle in routine psychiatric
practice (Chanut, Brown, & Dongier, 2005), its effects have been rarely quantified in
pharmacotherapy for pediatric psychopathology. Motivation for behavior change in the context
of psychopathology has most often been conceptualized in terms of the transtheoretical model
for change, which posits that patients are often at different stages of readiness for change. This
succession of stages include precontemplation (has not considered change), contemplation (has
some desire to change, but also some desire to maintain the status quo and has not initiated
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change), preparation (has started to take steps that lead to change), action (has initiated the
change process), and maintenance (working to retain changes that have been made; Prochaska &
DiClemente, 2005). Interventions tailored to specific stages of changes have displayed efficacy
in changing behaviors ranging from smoking cessation to physical activity promotion (Cahill,
Lancaster, & Green, 2010; Marshall et al., 2003), and while it was originally derived in the
context of substance use disorders, the relationship between readiness for change and outcome in
a number of psychotherapy approaches has been identified through meta-analysis (Norcross,
Krebs, & Prochaska, 2011). The transtheoretical model has proven quite flexible, permitting for
application to a wide range of behaviors (including exercise, domestic violence, and organ
donation) and in a broad array of treatment settings, ranging from primary care to college
campuses (Lundahl et al., 2013; Prochaska, Redding, & Evers, 2008).
In considering pediatric psychiatry, parental motivation for change has been identified to
predict adherence to psychiatric medication (De Nadai, 2013), and better outcomes have been
found in pharmacotherapy for depressed adolescents who are in the action stage of change at
baseline (Lewis et al., 2009). While data are limited with youth, higher levels of
precontemplation have been associated with less change during pharmacotherapy for adults with
obsessive compulsive disorder (OCD; Pinto, Pinto, Neziroglu, & Yaryura-Tobias, 2007).
Unfortunately, stages of change research has received relatively little attention in psychiatry,
despite the robustness of its supporting literature and its likely relevance for psychiatric research
and practice (Cole, Bogenschutz, & Hungerford, 2011). Notably, psychiatric disorders often
present barriers to motivation for change that prevent successful intervention for change in the
disorder itself (Dilallo & Weiss, 2009), creating a self-sustaining barrier to symptom change.
While patient motivation affects both distal patient symptom outcomes as well as proximal
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therapy process outcomes, the relative magnitude of its direct and indirect effects have rarely
been quantified for any health condition, and it remains an understudied variable in pediatric
psychiatric practice.
Considering the Role of Expectancies in Pediatric Psychiatry
Expectancies for psychiatric care can be distilled into two major aspects: what the patient
expects his/her role to be in treatment (role expectancies) and what the patient expects for
treatment outcome (outcome expectancies; Dew & Bickman, 2005; Glass, Arnkoff, & Shapiro,
2001). Outcome expectancies have received particular focus in mental health treatments
(Delsignore & Schnyder, 2007), and they have been identified to predict treatment outcomes in
psychotherapy through meta-analysis (Constantino, Arnkoff, Glass, Ametrano, & Smith, 2011),
including CBT for social phobia, fear of flying, and pediatric obsessive compulsive disorder
(Lewin, Peris, Lindsey Bergman, McCracken, & Piacentini, 2011; Price, Anderson, Henrich, &
Rothbaum, 2008; Safren, Heimberg, & Juster, 1997). Outcome expectancies do not exist in a
therapeutic vacuum but rather work jointly with other common factors, as patients with positive
treatment expectancies have been found to have stronger alliances (Connolly Gibbons et al.,
2003; Constantino, Arnow, Blasey, & Agras, 2005; Greenberg, Constantino, & Bruce, 2006;
Hersoug, Hoglend, Havik, & Monsen, 2010) and adhere better to psychological treatments
(Constantino, Ametrano, & Greenberg, 2012). This mechanistic relationship with alliance may
be particularly strong, as Joyce et al. (2003) found that alliance could account for approximately
one-third of the relationship between expectancies on outcome. Motivation for change has also
been associated with outcome expectations (McKee et al., 2007), though expectancies are
distinct from motivation, as patients may be motivated for change yet still not expect noteworthy
positive changes from therapy (Arnkoff, Glass, & Shapiro, 2002). This construct distinction has
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also been observed in pediatric psychotherapy, where parent outcome expectancies have been
found to predict adherence above and beyond parent motivation for treatment (Nock, Ferriter, &
Holmberg, 2006).
Despite the wide ranging effects observed for psychological treatments, expectancies
have received comparatively little attention in psychopharmacological interventions. With regard
to extant data, adolescents’ outcome expectations for depression treatment have predicted
outcomes across psychological and psychopharmacological modalities (Curry et al., 2006), and
similar findings have been found in adult depression (Sotsky et al., 1991). Distinguishing
patients with high and low expectations may provide a particularly stark contrast, as 90% of
patients with strong expectancies showed treatment response in a single-blind trial of reboxetine
for depression, in comparison to 33% of patients with low expectancies (Krell, Leuchter,
Morgan, Cook, & Abrams, 2004). It has been argued that common factors account for a majority
of variance in adult antidepressant therapy for depression, and in particular expectancies may be
a central mechanism for this effect (Kirsch, 2013). Alliance has also been demonstrated as a
mediating mechanism whereby expectancies exert outcome effects in pharmacotherapy for both
unipolar and bipolar depression (Gaudiano & Miller, 2006; Meyer et al., 2002). In addition to
these findings in depressive disorders, outcome expectancies along with perceived quality of
clinicians’ explanations of medications have been related to adherence in ADHD treatment (e.g.,
Berger, Dor, Nevo, & Goldzweig, 2008; McNicholas, 2012).
Troublingly, there may be lower expectations for primarily pharmacological approaches.
Rapaport et al. (1996) found that when surveying depressed patients about possible sources of
successful relief, medication alone was perceived as the least likely to help (8%), relative to
talking therapy alone (25%) and combined medication and talk therapy (62%). Lax et al. (1992)
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also found that patients with OCD had stronger treatment expectations for psychological
treatment relative to pharmacotherapy, though expectations were strong for both treatment
modalities. Expectancies may also impact trials of clinical compounds, as response rates are
higher in antidepressant trials when the medication under evaluation is compared to another
active medication as opposed to placebo (Rutherford, Sneed, & Roose, 2009). There are some
data that indicate that this finding may be due to higher expectancies for symptom reduction,
given that when patients are certain they are receiving active treatment they expect better
outcomes, as opposed to placebo-controlled trials where patients are uncertain if they are
receiving treatment that will be helpful (Rutherford, Sneed, Devanand, Eisenstadt, & Roose,
2010).
The powerful influence of outcome expectancies is well known in other areas of
medicine. Indeed, many physicians attempt to capitalize on their effects - over half of surveyed
physicians have reported that in the prior year, they have prescribed medications to raise patient
expectations as opposed to using them primarily for their original intended therapeutic effects
(Tilburt, Emanuel, Kaptchuk, Curlin, & Miller, 2008). There is some evidence that expectancy
itself works through neural mechanisms that regulate the experience of emotion (Enck,
Benedetti, & Schedlowski, 2008; Rutherford et al., 2010), and thus expectancy enhancing
interventions (Constantino et al., 2012) are not completely independent from biological
interventions. However, the role of outcome expectancies for medication therapy in pediatric
psychiatry remains poorly understood, with regard to both direct treatment effects as well as
indirect effects through variables such as adherence and alliance.
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Considering the Influence of Alliance, Motivation, and Expectancies on Adherence in the
Context of Outcome in Pediatric Psychiatry
A conceptual model of how common factors can affect psychiatric outcomes can be
found in Figure 1. This figure illustrates several notable facets. First, direct effects on outcome
are expressed by separate constructs including alliance, motivation, and expectancies, which
frequently have been amalgamated into a generic unitary placebo construct. Second, these
common factors are addressed for both parents and children through multi-informant reporting,
permitting comparisons among them. Third, mechanisms of effects are incorporated, with
alliance and adherence both functioning as mediators of improved psychiatric outcomes. At
present, while placebo effects have been identified to account for a substantial amount of
outcomes in pharmacotherapy (Leucht, Hierl, Kissling, Dold, & Davis, 2012), few attempts have
been made in the psychiatric literature to quantitatively break down the nature of these placebo
effects. This limits treatment targeting, as the proportion of outcomes attributable to different
common factors and different treatment participants has not been identified. This model also
readily includes potential moderators. For example, adherence rates may well differ for children
of different ages, given that parents often take more responsibility for medication administration
for younger youth relative their older counterparts (Hsin, La Greca, Valenzuela, Moine, &
Delamater, 2010).
Implications of the Present Study
While it is logical that psychosocial variables affect pediatric psychiatric treatment, the
research base is sparse with regard to their effects on outcome. Accordingly, a number of
important implications stand to follow from an empirical investigation of their mechanistic
effects. Most directly, these factors are likely to be associated with improved psychiatric
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outcomes, and highlighting their roles in a quantitative manner could lead to subsequent targeted
interventions to improve relevant behavior. This process fosters personalized medicine as
alliance, motivation, and expectancies could be measured via brief questionnaires during routine
clinical care, and patients who have undesirable values on any of these metrics could receive a
targeted intervention. At present such judgments (if made at all) are done through clinical
judgment, which is an inferior process compared to evaluation by actuarial means (Dawes,
2005). Currently, there exists little guidance beyond clinical intuition regarding how much
difference these variables make in pharmacotherapy outcomes for mental disorders in children.
Given that psychiatric drug development has lagged behind that of other medication classes
(Cowen, 2011), this approach provides a new avenue for gains in symptom reduction, via
adjustment of concurrent parameters of therapy. This approach has some parallel, as a number of
advances in chemotherapy over the past 40 years have been made by adjusting the administration
parameters of existing agents (Roberts & Thomas, 2005). In addition, an increased focus on
common therapy factors could facilitate safety monitoring of these psychotropic agents, as
improving the patient-provider relationship and patient motivation to engage actively in
treatment could reduce acute discontinuation and foster communication channels for reporting of
problems before they escalate. It also reintroduces the nature of therapy into psychiatric care, as
a brief medication check has become established as a standard of care in pediatric psychiatry
(Pruett, Joshi, & Martin, 2010).
Additionally, these findings could be used to improve the training of medical providers.
Strong alliances are not inherent to all clinician-patient relationships, and significant variability
has been detected among therapists with regard to the quality of alliances (Del Re, Flückiger,
Horvath, Symonds, & Wampold, 2012). Challenges also exist in maintaining professionalism
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while also forming a strong individual relationship with patients (Priebe & McCabe, 2008), and
tension or degradation in the therapeutic relationship (known as “ruptures”) in the alliance can
impair treatment. However, alliance ruptures also provide the opportunity for skillful clinicians
who repair such ruptures in psychotherapy to obtain particularly strong clinical outcomes
(Safran, Muran, & Eubanks-Carter, 2011). In this context, a number of psychosocial
interventions have been designed to improve adherence in pediatrics, which often focus on CBT
and/or motivational interviewing (MI) techniques (Dean, Walters, & Hall, 2010; Haynes,
Ackloo, Sahota, McDonald, & Yao, 2008). These interventions can be delivered by allied
providers for both psychiatric and non-psychiatric conditions (e.g., Rubio-Valera et al., 2011).
There is evidence that MI can be successfully taught to medical providers, resulting in changes in
physician behavior and enhanced patient outcomes (Soderlund, Madson, Rubak, & Nilsen,
2011). Specific training to improve alliances with psychiatric medication providers has also
improved both adherence and outcome to psychotropic medication interventions in adults (Byrne
& Deane, 2011), and expectancy enhancement manuals could also be adapted for child
psychiatry. The effects of clinician skills have been shown in psychiatric treatment, as one study
has found that a positive response to pharmacotherapy was only seen by patients who had a
clinician who was a skilled communicator (van Os et al., 2005). Still, the research base is limited
with regard to physician-patient communication in psychiatry, to which the present study can
contribute.
Data generated from this investigation can also highlight mechanisms of outcome, as
little is known about the process by which the common factors and the placebo process operate
in pediatric psychiatry. Given that placebo and common factor effects can account for a
significant proportion of pharmacotherapy outcomes, the field currently has a lack of knowledge
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about precisely why a number of medications are effective (e.g., SSRIs; Fernandez & Gaspar,
2012). It has been questioned whether the clinician-patient relationship is an adjuvant that fosters
the implementation of active medications, or whether it provides an additive effect above and
beyond pharmacotherapy (Priebe & McCabe, 2008). The present study is the first in pediatric
psychiatry to separate effects due to pharmacotherapy and effects due to common factors
elements.
Results from this investigation may also affect the practice of subsequent research. Poor
adherence to psychiatric medication can be a common confound in the results of clinical trials
(Case, 2011), reducing the ability to accurately identify the degree of symptom change due to
medication administration and possibly attenuating efficacy estimates. In another context, a
medication may have a large effect, but if the common factors also have large effects, the
observed effects of the medication may be washed out in a between-groups comparison. These
data would provide an initial metric to estimate how much common factors influence should be
observed when planning clinical trials.
The purpose of this study is to evaluate the role of psychosocial variables in pediatric
psychiatric practice. It was hypothesized that stronger motivation, expectancies, alliances, and
adherence would be associated with reductions in psychiatric symptoms. Specifically, it was
predicted that these psychosocial variables would work in tandem, with pretreatment
expectancies and motivation being predictive of stronger alliances, which would be predictive of
stronger adherence and subsequent outcomes. Understanding psychosocial mechanisms of
outcome in pediatric psychiatry highlights a way forward to improve future clinical care, and
provides a framework to help understand the assumptions underlying prior research. While
medication is often attributed as the active intervention in pediatric psychiatric practice, this
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study proposes to reframe contemporary psychiatric practice and partition outcomes into a
variety of meaningful components. This investigation stands to open up for consideration
significant changes to clinical practice, future research, and the training of medical providers.
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Method
Participants
Participants were 159 youth ages 7-17 years presenting for psychiatric treatment
(M=11.79, SD=3.10), along with their parents and treating clinicians. Participants were 42.1%
female, and the ethnic/racial distribution was 78.6% Caucasian, 1.9% African American, 7.5%
Hispanic, 0.6% Pacific Islander, 0.6% as Middle Eastern, 10.1% identifying as “other,” and 0.6%
not providing information on race/ethnicity. Participants were recruited from one of three sites:
The USF Silver Center for Child Development (USF; n=65), the All Children’s Hospital
Pediatric Psychiatry Clinic (ACH n=63), and the Rothman Center for Pediatric Neuropsychiatry
(RCN n=31). The USF and ACH sites are not-for-profit outpatient clinics that serve youth with a
broad array of psychiatric problems, while the RCN site is a non-profit specialty clinic that
focuses on pediatric OCD and related conditions (e.g., anxiety disorders, tic disorders).
Participating patients were recruited from those referred to board-certified psychiatrists or
supervised child and adolescent psychiatry fellows for care as usual, with no circumscribed limit
on the number of patients seen per individual provider. Through the normal course of care,
clinical diagnoses were established through a clinical interview utilizing all available
information, as recommended by Klein, Dougherty, and Olino (2005) as well as Silverman and
Ollendick (2005). To add further support for diagnoses, a clinical level of symptomology as
indicated by either child or parent via self-report (on the MASC-ADI, CDI-2-SF, YSR, or
CBCL) was used as a requirement for study inclusion using a diagnostic “or” rule (Piacentini,
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Cohen, & Cohen, 1992). No identifiable data collected from participating youth and
parents regarding alliance, motivation, expectancies, or adherence was shared with
participating clinicians.
Prescriptions were provided by study clinicians to 127 participants, and a total of
231 observations were available for analysis (1.57 medications prescribed per participant
who received medication). Common types of medications provided included stimulants
(n=56), serotonin reuptake inhibitors (n=58), alpha-2 agonists (n=24), and atypical
antipsychotics (n=17). Common diagnoses assigned to participants included externalizing
(n=40), internalizing (n=94), neurodevelopmental (n=38), ADHD (n=87), and tic
disorders (n=23). Regarding other interventions received, 39.8% of those who responded
to 1-month follow-up calls reported receiving concurrent treatment from another provider
by that timepoint, and 52.9% of respondents who responded to 3-month follow-up calls
reported receiving concurrent treatment from another provider by that timepoint.
Procedures
After obtaining informed consent, measures pertaining to questionnaires on
motivation and expectancies were completed before participants’ scheduled initial
clinical visit, and questionnaires related to alliance were completed immediately after the
clinical session. At one and three months after the initial study intake session, study
participants received follow-up assessments via phone. A timetable indicating the
timepoint at which each self-report measure was administered (baseline, 1-month followup, or 3-month follow-up) can be found in Table 1.
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Measures
All study measures free of non-redistributive copyright can be found in Appendices A-K.
Parent and child rated measures.
University of Rhode Island Change Assessment (URICA; McConnaughy et al., 1983).
The URICA is a 32-item measure of motivation for behavior change in mental health treatment.
Items are rated on a 5-point Likert scale ranging from “strongly disagree” to “strongly agree.”
The URICA has four subscales (precontemplation, contemplation, action, and maintenance), and
the URICA total score is calculated by subtracting the precontemplation subscale from the sum
of the contemplation, action, and maintenance subscales. Higher scores reflect greater readiness
for behavior change. Modification of the URICA for different populations is encouraged (Rossi,
1995) and such modification has been successfully employed in other studies (e.g., Dozois,
Westra, Collins, Fung, & Garry, 2004; Greenstein, Franklin, & McGuffin, 1999). In the present
investigation, minor modifications were made to certain relevant items (e.g., changing the word
“psychology” to “psychiatry”) on both parent and child forms to properly address their role in
treatment. The child form focuses on child readiness for change, and the parent form also focuses
on readiness for child behavior change (e.g., what is their perception of the child’s problem, are
parents contemplating the concept that their child needs to change). Similar modifications have
displayed acceptable internal consistency in youth ages 7-17 years (alpha=.71; Keeley, Geffken,
Ricketts, McNamara, & Storch, unpublished data), as well as in adults (alpha=.79; Dozois et al.,
2004). Pretreatment child URICA scores have been shown to be associated with higher
pretreatment child anxiety reported via the MASC (r=.33, Keeley et al., unpublished data), and
have been observed to predict positive outcomes in adult psychotherapy (Norcross, Krebs, &
Prochaska, 2011).
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Clinician rated measures.
Therapeutic Alliance Quality Rating (TAQ-R; Bickman et al., 2010). The TAQR is a standardized clinician rating of therapeutic alliance with other treatment parties
(i.e., parents and children). It consists of a 1-item rating for the perceived alliance with
each therapeutic party that asks, “In this session, how would you describe your
relationship with this youth/caregiver.” The TAQ-R is rated on a 5-point Likert scale with
responses ranging from “very poor” to “excellent.” In the development of the TAQ-R, an
initial item pool of 52 items was generated to address the bond, task, and goals elements
of therapeutic alliance as specified by Bordin (1979), though it was determined through
item response theory and classical psychometrics that single item TAQ-R ratings
provided largely redundant information for clinician-rated alliance (Bickman et al.,
2010). Variability in TAQ-R scores has been observed for both clinician ratings of
alliance with the parent (M=4.22, SD=0.71) and youth (M=3.80, SD=0.82) in a large
clinical sample (Bickman, et al., 2010), and TAQ-R scores have been found to be
predictive of treatment outcome (Bickman, et al., 2012).
Parent rated measures.
Working Alliance Inventory-Short Form (WAI-SF; Horvath & Greenberg,
1989; Tracey & Kokotovic, 1989). The WAI-SF is a parent-rated measure of therapeutic
alliance with the treating clinician. It was originally designed to measure therapeutic
alliance in adult psychotherapy, and has been successfully adapted to assess therapeutic
alliance of parents of children in psychotherapy (Hawley & Garland, 2008). It consists of
12 items rated on a 1-7 Likert scale ranging from “never” to “always,” and focuses on
parental agreement on the tasks to be performed in their child’s treatment, parental
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agreement with the clinician on the goals of their child’s treatment, and the therapeutic bond
between parent and clinician. When used with parents of children in psychotherapy, it has
demonstrated acceptable internal consistency and test-retest reliability (alpha>.93, 6-month testretest r=.77; Hawley & Garland, 2008) and has predicted improvements in youth
psychopathology and parent satisfaction during psychosocial treatment (Hawley & Garland,
2008).
Credibility/Expectancy Questionnaire-Parent Version (CEQ-P; Nock, Ferriter, &
Holmberg, 2006). The CEQ-P is a measure of parental outcome expectations and treatment
credibility. It consists of 6 items, with factor analysis supporting a two-factor model of 3 items
each (falling along the lines of treatment credibility and expectancies). The present study
employs the expectancy subscale of the CEQ-P, which has demonstrated strong internal
consistency (alpha=.88) and adequate test-retest reliability after 6-8 sessions of psychotherapy
(r=.52; Nock, et al., 2006). Scores on the CEQ-P have been associated with parent motivation to
participate in treatment, and the CEQ-P expectancy subscale has correlated with parental
treatment adherence in pediatric psychotherapy (Nock, et al., 2006).
Child Behavior Checklist (CBCL; Achenbach & Rescorla, 2001). The CBCL is a
parent-report measure of internalizing and externalizing symptoms in children over the past six
months. It consists of 118 items rated on a 0-2 Likert scale ranging from “not true” to “very
true,” and total scores are computed for overall internalizing and externalizing behavior. Based
on a normative sample, internal consistency has been observed to be .90, .94, and .97 for the
internalizing, externalizing, and total scores, respectively (as measured by Cronbach’s alpha),
and eight day test-retest reliability has been observed at .91, .92, and .94 for the internalizing,
externalizing, and total scores, respectively (Achenbach & Rescorla, 2001). A t-score of 60 or
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above has been found to differentiate youths based on treatment referral status, where
treatment referral status can be determined with 85% accuracy on the CBCL (Achenbach
& Rescorla, 2001).
Brief Progress Monitor-Parent Version (BPM-P; Achenbach, McConaughy,
Ivanova, & Rescorla, 2011). The BPM-P is a measure designed to track changes in child
psychopathology throughout treatment. It includes 19 parent-rated items that are scored
on the same 0-2 Likert scale as the CBCL. It evaluates internalizing and externalizing
psychopathology as well as symptoms of inattentiveness, and consists of a subset of items
from the Child Behavior Checklist (Achenbach & Rescorla, 2001) that were identified
via factor analysis with the intention of providing a brief, reliable, and valid measure of
symptom tracking over time. Internal consistency (as measured by Cronbach’s alpha) has
been observed to be .80, .85, .88, and .92, for the internalizing, inattentiveness,
externalizing, and total scores, respectively (Achenbach, McConaughy, Ivanova, &
Rescorla, 2011). Eight day test-retest reliability has been observed to range from .81 to
.85 for each of these scores, and the total score has been shown to effectively identify the
presence of a psychiatric diagnosis and the use of mental health services in the prior year
(Tarren-Sweeney, 2013).
Brief Medication Questionnaire (BMQ; Svarstad, Chewning, Sleath, &
Claesson, 1999). The BMQ is a parent-rated measure of adherence to pharmacotherapy.
The 7-item medication regimen screen portion of the BMQ was employed via phone
follow-up. Brief Medication Questionnaire items have shown test-retest stability (Rickles
& Svarstad, 2007), have correlated with adherence measurement via electronic
monitoring (Shi et al., 2010), and have been used successfully to evaluate psychiatric
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medication administration with pediatric caregivers (Dean, Wragg, Draper, & McDermott,
2011). Percentage of medication adherence over the prior week can be calculated following
procedures described by Curtin, Keller, and Svarstad (1999), which consist of dividing the
number of doses missed over the past week by the number of prescribed doses indicated for the
week, and then subtracting this value from 1.
Service Assessment for Children and Adolescents (SACA; Stiffman et al., 2000). The
SACA is a measure of service utilization in children and adolescents. In its original form, it
consists of 30 items administered via parent interview. It has demonstrated excellent agreement
in service utilization measurement when compared to service records (kappa=.76; Hoagwood et
al., 2000), and it is frequently modified to match specific patient populations while maintaining
reliability and validity (Stiffman et al., 2005). To reduce participant burden, a 13-item version
was used in the present investigation, which combines items regarding outpatient, inpatient, and
community-based services while still covering all relevant services received.
Frequency, Intensity, and Burden of Side Effects Rating/Patient Rated Inventory of
Side Effects (FIBSER/PRISE; Wisniewski et al., 2006). The PRISE is a checklist of side effects
experienced during pharmacotherapy, and the FIBSER is a rating of the frequency, intensity, and
burden of side effects experienced from taking psychiatric medication. The PRISE (a 9-item
presence/absence checklist) is used to highlight relevant side effects before the administration of
the FIBSER (a 3-item measure rated on a 0-6 Likert scale). The FIBSER has demonstrated
strong internal consistency (alpha=.91-.93), and higher scores on the FIBSER have been
associated with treatment dropout in a randomized controlled trial for adult depression
(Wisniewski, Rush, Balasubramani, Trivedi, & Nierenberg, 2006). The FIBSER and PRISE were
originally designed for use with adults. They were modified to be used by parents to evaluate
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their child’s side effects for the present investigation; items have been inspected by a
board-certified child and adolescent psychiatrist (Dr. Mark Cavitt at the ACH study site)
to ensure item appropriateness for the study population.
Child rated measures.
Therapeutic Alliance Scale for Children-Revised (TASC-R; Shirk & Saiz,
1992). The TASC-R is a measure of youth therapeutic alliance in treatment. Its 12 items
are rated on a 4-point Likert scale and assesses bond with the clinician and agreement
with the clinician on therapeutic tasks. The TASC-R provides minor wording
modifications to the original TASC so that it can address therapeutic alliance at a specific
treatment session, whereas the original TASC measures alliance across multiple sessions
(Creed & Kendall, 2005). Internal consistency of the TASC-R has been demonstrated for
children ages 7-17 (alpha=.88-.92; Creed & Kendall, 2005; Keeley, Geffken, Ricketts,
McNamara, & Storch, 2011). Acceptable levels of test-retest reliability have been
observed over a period of five psychotherapy sessions (r=.60; Keeley et al., unpublished
data), and TASC-R scores at session 5 have predicted treatment outcome in CBT for
pediatric OCD (Keeley et al., 2011).
Credibility/Expectancy Questionnaire-Child Version (CEQ-C). The CEQ-C is a
child-rated assessment of outcome expectancies and treatment credibility. Its 6 items
were designed to parallel items on the adult CEQ (Devilly & Borkovec, 2000). It was
created for the present investigation due to the lack of empirically validated measures of
treatment expectancies for youth. The CEQ was originally developed as a modification to
the Expectancies Rating Questionnaire (ERQ; Borkovec & Nau, 1972) to reduce
confounding with treatment credibility observed in the ERQ. Similar content is shared
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among the measures, and the ERQ has been successfully used with youth ages 7 years and above
(Ollendick et al., 2009), suggesting appropriateness of item content for children. The present
study employs the expectancy subscale of the CEQ-C, which has three items that are rated on
either a 9- or 11-point Likert scale. When used with adults, this subscale has been observed to
have adequate internal consistency (alpha=79-.90), with a 1-week test-retest reliability value of
r=.82 (Devilly & Borkovec, 2000). The two-factor structure has been supported in adults by
confirmatory factor analysis, and expectancy subscale scores have been correlated with
reductions in anxiety and global distress during treatment for adult anxiety (Devilly & Borkovec,
2000).
Youth Self Report (YSR; Achenbach & Rescorla, 2001). The YSR is a child-report
measure of internalizing and externalizing behavioral problems in children that is intended to
parallel the CBCL. It consists of 112 items rated on a 0-2 Likert scale ranging from “not true” to
“very true or often true,” resulting in total scores for overall internalizing and externalizing
behavior. While originally designed for youths ages 11-17, the YSR has demonstrated strong
internal consistency for youth ages 7 and above, with Cronbach’s alpha values of .88-.89, .88.89, and .93 observed for the internalizing, externalizing, and total problems scales respectively
(Ebesutani, Bernstein, Martinez, Chorpita, & Weisz, 2011). A t-score of 60 or above has been
found to differentiate youths based on clinical referral status (Achenbach & Rescorla, 2001).
Items focusing on drug use and sexual behavior were not included, as it was not necessary to
expose younger participants to these items for the purposes of the present investigation, and
adjustments to YSR drug use items have been successfully employed in other investigations
(e.g., Substance Abuse and Mental Health Services Administration, 1999).
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Multidimensional Anxiety Scale for Children-Anxiety Disorders Index (MASCADI; March, Parker, Sullivan, Stallings, & Conners, 1997). The MASC-ADI is brief
measure of anxiety symptomology in children. It consists of 10 items rated on a 0-4 scale
that ranges from “never true about me” to “often true about me.” These items are a subset
of items from the 39-item MASC that were identified to best discriminate children with
anxiety disorders from nonclinical control participants. Psychometric adequacy has been
demonstrated with children ages 7-17 years, with an observed internal consistency of
alpha=.74 (Grills-Taquechel, Ollendick, & Fisak, 2008) and three month test-retest
reliability of r=.70 (March, Parker, Sullivan, Stallings, & Conners, 1997). When used as
a screening instrument to differentiate anxious children from nonclinical controls, the
MASC-ADI has displayed sensitivity values of .90-.95, specificity values of .84-.95, an
overall correct classification rate of 87-95%, and kappa values of .74-.90 (March, 1997).
The MASC-ADI has also been able to distinguish children with anxiety disorders from
nonclinical controls when using discriminant function analyses (Grills-Taquechel et al.,
2008; Rynn et al., 2006).
Children’s Depression Inventory-2nd Edition Short Form (CDI-2-SF; Kovacs,
2011). The CDI-2-SF is a child-rated measure of depressive symptoms intended for
children ages 7-17 that was empirically derived from the 28 item CDI-2 long form. Its 10
items are rated on a 0-2 scale and cover the affective, cognitive, and neurovegetative
aspects of pediatric depression, and a total score is produced to quantify overall severity
of depression. Internal consistency for the CDI-2-SF has been observed at alpha=.82, its
two week test-retest reliability has been indicated to be r=.77, and it is strongly correlated
with the CDI-2 long form (r=.95, p<.001; Kovacs, 2011). The CDI-2-SF has displayed
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sensitivity and specificity values of .84 and .77, respectively, when used to differentiate children
meeting DSM-IV criteria for major depressive disorder from matched controls (Kovacs, 2011).
For predicting clinician diagnosis, Kovacs (2011) recommends the CDI-2-SF in lieu of the
complete CDI, as it has displayed stronger psychometric properties for this purpose than the full
CDI-2 form (e.g., better test-retest reliability, better discriminant validity, and improved
sensitivity and specificity when using a clinical cutoff score of 6).
Analytic Plan
The present study design reflected multiple levels of nesting. Because multiple
medications were allowed for each patient at each timepoint, there were multiple observations
per timepoint, multiple timepoints per patient, multiple patients per clinician, and multiple
clinicians per site. To identify if method-based adjustments for nested data clustering were
necessary, design effects for all dependent variables were considered, where design effects
greater than 2 reflect a need to adjust estimates for clustering (Muthén & Satorra, 1995). Among
nesting variables (i.e., time, participant, clinician, and site), design effects were greater than 2
only for clinician and site. To address nesting by clinicians, the MLR-complex estimator was
employed for all analyses, with clinician specified as the clustering variable. To address nesting
by site, dependent variables in all analyses were predicted by dummy-coded site variables before
adding predictors and covariates, reflecting a fixed effects approach to clustering (as specified by
Cohen, Cohen, West, & Aiken, 2003). The distribution of adherence was nonnormal, with
disproportionate amounts of patients displaying either very low or very high adherence. This
nonnormality was addressed by use of the MLR-complex estimator.
All bivariate relationships tested as a part of study hypotheses are displayed in Figure 1.
Figure 1 shows a pattern of effects that reflect expectancies and motivation as pretreatment
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factors, which then affect subsequent alliance; alliance then affects adherence, and adherence
then affects treatment outcome. Relationships among variables that were not modeled as
unidirectional causes of one another were defined as exogenous, while endogenous relationships
were defined when variables were determined by other variables in the system. Relationships
among exogenous variables were evaluated by correlational methods, while relationships
between exogenous and endogenous variables were evaluated by regression methods.
Correlations tested were partial correlations (i.e., correlating the residuals after partialing out the
effects of site out of each variable, in order to account for site-based clustering). Regressions
were evaluated by first regressing dependent variables onto dummy-coded site, and then adding
hypothesized predictors to this model. To evaluate prediction of treatment outcome, 3-month
BPM-P scores were first regressed on both site and baseline scores, and then hypothesized
predictors were added to this model, reflecting a residualized regression. Outcomes were
considered separately for each BPM-P subscale (Internalizing, Externalizing, Attention
Problems).
Moderation of bivariate regressions was also considered, with the effects of each
individual moderator evaluated in separate models. Moderators included type of medication
(including stimulants, SRIs, atypical antipsychotics, alpha-2 agonists, and a comparison was also
made between patients who received medication at all and those who did not), disorder class
(including internalizing, externalizing, neurodevelopmental, ADHD, and tic-related disorders),
patient age, concurrent treatment as reported at 1- and 3-month follow-up, and respective
FIBSER items corresponding to frequency, intensity, and interference associated with side
effects. Medications were classified based on category definitions established in the Federal
Drug Administration National Drug Code Directory (Federal Drug Administration, 2017).
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Disorders were classified based on suggestions in the DSM-5 (American Psychiatric Association,
2013), which notes that a series of papers commissioned by Andrews (2009) shaped
classification schemes and provided further information regarding the rationale for
categorization. When the Andrews (2009) papers disagreed with final DSM-5 classification,
disorders in question were evaluated in their own class. This affected ADHD (which is
considered with neurodevelopmental disorders in DSM-5, but shows strong relationships with
externalizing disorders both conceptually and in the Andrews, 2009 papers) and tic disorders
(which were unclassified in the Andrews, 2009 papers and show limited phenomenological
overlap with other disorder classes evaluated in this study). Moderators were evaluated in
analyses if they were observed more than 15 times in the study sample in order to accommodate
central limit theory assumptions (Smith & Wells, 2006). Moderation models were computed by
adding the moderator and its product with the main effect to regression models; significant
moderation was evaluated based on the product term. All dichotomous moderators were dummycoded, and all continuous predictors were centered prior to creating moderator product terms
used in models. To evaluate the results of statistically significant moderation, simple slopes were
evaluated following procedures delineated by Preacher, Curran, & Bauer (2006). Simple slopes
were evaluated at low, medium, and high levels of study moderators (with medium levels
reflecting the mean of the moderator and low and high levels reflecting ±1 SD, or only with 0
and 1 reflecting low and high levels respectively for dummy-coded moderators). Because
moderators reflect post-hoc hypotheses, a Holm-Bonferroni correction (Holm, 1979) was used
on all moderation analyses to determine statistical significance. This correction limits familywise
Type I error while retaining more power than the traditional Bonferroni correction. As
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recommended by Fairchild and McQuillin (2010), significance of simple slopes was tested via
unstandardized coefficients. Standardized coefficients are reported to facilitate interpretation.
Figure 1 also implies mediation-based relationships. Indirect effects were tested for all
variables that showed significant a and b paths in main effect and/or moderated models (e.g., if
alliance significantly predicted adherence and then adherence significantly predicted outcomes in
separate bivariate models). Significant direct effects were not required to consider a test of
moderation given that a number of processes can lead to significant indirect effects in the
absence of direct effects (Hayes, 2013). Moderators that were significant after Holm-Bonferroni
correction were also included in respective indirect models (which reflects a process of
moderated mediation; please see Figure 2 for a visual depiction of modeled indirect paths).
Simple slopes in moderated mediation models were evaluated following procedures delineated
by Hayes (2013), and Mplus implementations of these procedures provided by Stride, Gardner,
Catley, and Thomas (2015) were employed when available. These procedures focus on
evaluating the significance of the product of the indirect paths (i.e., ab for a single moderator or
abc for 2 sequential moderators), and also take into account the direct effect of X on Y (c’).
Standard errors for tests of indirect effects were calculated based on the delta method. As with
other analyses, site-based clustering was accounted for by including dummy-coded site variables
on all DVs in indirect effect models. Inconsistent mediation was observed when the indirect
effect had the opposite sign of direct effects (MacKinnon, Fairchild, & Fritz, 2007).
With respect to effect sizes, small, medium, and large effect sizes respectively apply to
partial correlations of .1, .3, and .5, and regression model R2 values of .01, .09, and .25 (Cohen,
1988). For main effects in regression models, R2 was evaluated based on the amount of variance
a main effect accounted for above and beyond site (defined as ME-R2 for main effects) and for
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moderators, R2 was evaluated based on how much variance was explained by adding the
moderator and the moderator product term to the main effect model (defined as ΔR2). Effect
sizes reported for indirect effects were based on recommendations by Wen and Fan (2015) to
report standardized estimates of the indirect, direct effect, and total effects. To illustrate, Wen
and Fan (2015) provided an example based on standardized estimates, where if the indirect effect
is 0.2, the direct effect is 0.3, and the total effect is 0.5, then it can be interpreted that for a
change of 1 standard deviation in X, Y will change 0.5 standard deviations, of which 0.2
standard deviations are attributable to the indirect effect and 0.3 standard deviations are
attributable to the direct effect. Regarding measure reliability, internal consistency was evaluated
through the use of Cronbach’s alpha (Cronbach, 1951), with alpha values of .70 or higher
considered acceptable (Nunnally, 1978).
Data were missing at a rate of 26.4% on all variables modeled in Figure 1. The principal
contributor to these missing data was follow-up response rate, as 52.2% of participants
participated in 1-month follow-up and 53.5% of participants participated in 3-month follow-up.
In addition, 20 youths among participating families (12.6%) did not provide assent to
participation, for reasons including parents not wanting to add additional work to children during
a clinic visit (n=4), children preferring to engage in other activity instead of participating (n=3),
child/parent expressing concern that the child would be able to comprehend the self-report
assessments (n=6), and 7 families did not provide a specific reason for choosing not to provide
child assent. In cases of parental consent but lack of child assent, parents were willing to
continue to provide behavioral data from themselves, but no child report was provided. To
address missing data, several measures were taken. All hypothesis tests were estimated using
full-information maximum likelihood estimation in Mplus version 7 (Muthén & Muthén, 2012).
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Auxiliary variables were used to aid in the estimation of missing data via a saturated correlates
model; auxiliary variables included all common factors as rated by parents, children, and
clinicians, as well as baseline scores on all BPM-P subscales. The effects of clinician and site
were also included as auxiliary variables in all models (as a part of accounting for their clustering
effects in all models). Means and variances of all predictors and covariates were also estimated
via FIML estimation (as opposed to assumed as fixed) to aid in parameter estimation in the
presence of missing data.
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Results
Descriptive Variable Characteristics and Relationships Among Exogenous Variables
Descriptive statistics for the present sample can be found in Table 2; internal consistency
for all measures was acceptable. Correlations among exogenous study variables can be found in
Table 3. Among pretreatment exogenous variables, child motivation (via the URICA-C) was
significantly correlated with all other pretreatment exogenous variables, including the CEQ-C
(partial r=0.34, p=.002), the CEQ-P (partial r=0.16, p=.031), and the URICA-P (partial r=0.23,
p=.006). Regarding relationships among alliance reporters, clinician-reported alliance with
parents was significantly related with parent-rated alliance (via the WAI-SF; partial r=0.26,
p<.001) and clinicians’ ratings of their alliance with participating children (via the TAQ-R-P;
partial r=0.26, p=.008). Additionally, clinician ratings of their alliance with children was
significantly correlated with child ratings of alliance (via the WAI-SF; partial r=0.47, p<.001).
The correlation among adherence measurements at follow-up at 1-month and 3-months was also
significant (partial r=0.55, p<.001).
Bivariate Predictive Relationships
Bivariate predictive relationships for all main effects and significant moderators of main
effects can be found in Table 4.
Prediction of alliance by motivation and expectancies. Child-rated alliance showed a
significant relationship with child motivation (b=0.52, p<.001, ME-R2=.24). Child-rated alliance
had a significant relationship with child expectancies and parental motivation, though these
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effects varied in the presence of moderators. Child expectancies predicted child alliance for
youth without ADHD (b=0.62, p<.001, ME-R2=0.08, ΔR2=0.15). It also predicted child alliance
for youth on alpha-2 agonists, though it showed a positive relationship for youth who were not
on these medications (b=0.31, p<.001, ME-R2=0.08, ΔR2=0.16) and a negative relationship for
youth who received them (b=-0.02, p<.001, ME-R2=0.08, ΔR2=0.15). It also only predicted child
alliance for youth who had low (b=1.03, p<.001, ME-R2=0.08, ΔR2=0.26) and medium (b=0.36,
p<.001, ME-R2=0.08, ΔR2=0.26) intensity of side effects. Child alliance was also predicted by
parent motivation, but showed a varying relationship based on concurrent treatment received
during the 3 months post-baseline; youth who did not receive concurrent treatment during this
time period showed a negative relationship between child alliance and parent motivation (b=0.26, p<.001, ME-R2=0.01, ΔR2=0.12), while those who did receive concurrent treatment
showed a positive relationship between these variables (b=0.18, p=.012, ME-R2=0.01,
ΔR2=0.12). Parent-rated alliance was significantly predicted by parental expectancies (b=0.22,
p=.034, ME-R2=0.05) and parent motivation (b=0.30, p<.001, ME-R2=0.09). It was also
predicted by child motivation, but only for youth who were prescribed atypical antipsychotics
(where it had a negative relationship for these youth; b=-0.21, p<.001, ME-R2=0.00, ΔR2=0.05).
Among pretreatment exogenous variables, the only one that significantly predicted
clinician-rated alliance with children was child motivation (b=0.21, p=.014, ME-R2=0.04). With
regard to predicting clinician-rated alliance with parents, child and parent motivation were found
to be significant predictors of clinician-rated alliance with parents, though both of these effects
were found to be moderated. The effect of child motivation on TAQ-R-P scores was moderated
by prescription of atypical antipsychotics, with a stronger relationship for youth who were not
prescribed these medications (b=0.27, p=.005, ME-R2=0.04, ΔR2=0.09), though a significant
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positive relationship was also found for youth who received these medications (b=0.03, p<.001,
ME-R2=0.04, ΔR2=0.09). The effects of parent motivation on TAQ-R-P scores were moderated
by externalizing diagnosis; a negative relationship between motivation and alliance was found
for youth without externalizing diagnoses (b=-0.22, p=.021, ME-R2=0.02, ΔR2=0.10), whereas a
positive relationship was found for those who did have an externalizing diagnosis (b=0.22,
p<.001, ME-R2=0.02, ΔR2=0.10). Child and parent expectancies were not significantly related
with clinician-rated alliance with parents.
Prediction of medication adherence by motivation, expectancies, and alliance. At 1month follow-up, medication adherence was negatively associated with parental expectancies
(b=-0.34, p<.001, ME-R2=0.11) and child motivation (b=-0.28, p=.029, ME-R2=0.07). It also
exhibited a positive relationship with clinician-rated alliance with children for participants who
were prescribed atypical antipsychotics (b=0.14, p<.001, ME-R2=0.00, ΔR2=0.05). All other
psychosocial variables were nonsignificant predictors of medication adherence at 1-month
follow-up. The only significant predictor of medication adherence at 3-month follow up was
parent expectancies, which was again associated with lower adherence (b=-0.19, p=.014, MER2=0.05).
Prediction of treatment outcome by adherence, motivation, expectancies, alliance,
and medication adherence. With regard to predicting change in externalizing symptoms, all
significant predictors of BPM-P Externalizing scores reflected a worsening of symptoms. This
included child expectancies for youth with tic disorders (b=0.04, p<.019, ME-R2=0.01,
ΔR2=0.06), child motivation for youth with tic disorders (b=0.14, p<.001, ME-R2=0.00,
ΔR2=0.09), and parent alliance for youth who did not have externalizing disorders (b=0.40,
p<.001, ME-R2=0.01, ΔR2=0.03).
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With regard to predicting change in internalizing symptoms, clinician-rated alliance with
parents was associated with a reduction in symptoms for youth prescribed atypical antipsychotics
(b=-0.20, p<.001, ME-R2=0.00, ΔR2=0.06). An increase in internalizing symptoms was
associated with higher levels of child motivation (b=0.27, p<.001, ME-R2=0.06), child
expectancies for youth who were prescribed atypical antipsychotics (b=0.13, p<.001, MER2=0.00, ΔR2=0.04), and those prescribed alpha agonists who had higher levels of medication
adherence at 1-month follow-up (b=0.83, p<.001, ME-R2=0.03, ΔR2=0.07). Higher parent
motivation was associated with internalizing symptom reduction in youth who did not receive a
prescription at all (b=-0.18, p=.023, ME-R2=0.00, ΔR2=0.04), but symptom increases in youth
who did receive a prescription (relative to no prescription at all; b=0.08, p<.001, ME-R2=0.00,
ΔR2=0.04). Higher child alliance was associated with internalizing symptom reduction in youth
who did not receive a prescription of atypical antipsychotics (b=-0.22, p=.019, ME-R2=0.02,
ΔR2=0.09), but symptom increases in youth who were prescribed atypical antipsychotics
(b=0.03, p<.001, ME-R2=0.02, ΔR2=0.09).
With regard to predicting change in attention problems, a reduction in attention problems
was associated with child alliance (b=-0.15, p=.047, ME-R2=0.02) as well as parent expectancies
for children who experienced side effects at medium (b=-0.24, p<.001, ME-R2=0.07, ΔR2=0.18)
and high (b=-0.77, p<.001, ME-R2=0.07, ΔR2=0.18) levels of intensity. Worsening of attention
problems was seen for higher levels of clinician-rated alliance with parents for children who had
not received concurrent treatment by 3-month follow-up (b=0.42, p<.001, ME-R2=0.00,
ΔR2=0.04).
Relationships of common factors with change in attention problems varied at different
levels of moderators. Higher parent alliance was associated with a reduction in attention
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problems for children who experienced low levels of functional interference due to side effects
(b=-0.54, p=.002, ME-R2=0.02, ΔR2=0.20), but a worsening of symptoms for youth who
experienced high levels of functional interference due to side effects (b=0.75, p<.001, MER2=0.02, ΔR2=0.20) and youth who had received concurrent treatment at 3-month follow-up
(b=0.35, p<.001, ME-R2=0.02, ΔR2=0.16). Additionally, greater adherence at 1-month follow-up
was associated with a reduction in attention problems for youth with low intensity of side effects
(b=-0.49, p=.015, ME-R2=0.01, ΔR2=0.17), but an increase in symptoms for youth with high
intensity of side effects (b=0.61, p<.001, ME-R2=0.01, ΔR2=0.17).
Indirect Predictive Relationships (Mediation)
Results from analyses of therapeutic processes can be seen in Table 5, which correspond
to the models depicted in Figure 2. With regard to the process externalizing symptom change,
child motivation had an indirect influence on symptom reduction through parent alliance for
youth prescribed atypical antipsychotics (ab=-0.48, p=.013). Inconsistent mediation was
observed in this case for children who had tic disorders (i.e., the direct effect was associated with
an increase in symptoms for children with tic disorders whereas the indirect effect was associated
with a decrease in symptoms; c’=1.11, p<.001). Parent motivation was also indirectly associated
through parent alliance with an increase in externalizing symptoms for children who did not have
an externalizing diagnosis (ab=0.18, p=.010)
With regard to the process of influence of internalizing symptom change, multiple
expectancy factors showed an indirect effect on change through alliance. In particular, the effect
of child expectancies on change in internalizing symptoms through child alliance varied
depending on moderators. Child expectancies were associated with a worsening of symptoms for
youth who were prescribed atypical antipsychotics but did not have an ADHD diagnosis
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(ab=0.59, p<.001). In the context of youth with either/or prescriptions of alpha-2 agonistics or
atypical antipsychotics, higher child expectancies were associated with a worsening of symptoms
for youth who were prescribed either alpha-2 agonists (ab=0.26, p=.016) or atypical
antipsychotics (ab=0.28, p=.012), but not for youth who were prescribed both of these
medications simultaneously (ab=-0.96, p=.061) or who were not prescribed either of these
medications (ab=-0.07, p=.079). The indirect effect of child expectancies on internalizing
symptom change through child alliance also differed for youth prescribed atypical antipsychotics
in the context of side effect intensity. Higher child expectancies through child alliance were
associated with symptom reduction for children who were not prescribed atypical antipsychotics
and had either a low (ab=-0.24, p=.015) or medium intensity of side effects (ab=-0.11, p=.018),
but were associated with a worsening of symptoms for youth who did received these medications
and also experienced either low (ab=0.80, p=.010) or medium (ab=0.36, p=.030) intensity of side
effects.
Motivation also had multiple indirect effects on internalizing symptom outcome. Child
motivation indirectly predicted through child alliance an improvement of internalizing symptoms
for children who were not prescribed atypical antipsychotics (ab=-0.31, p=.004); however,
inconsistent mediation was found in this case as the direct effect of child motivation was
associated with a worsening of internalizing symptoms (c’=0.57, p<.001). Parent motivation also
predicted internalizing symptoms through clinician-rated alliance with parents; a worsening of
symptoms was seen for youth who were prescribed atypical antipsychotics and did not have an
externalizing diagnosis (ab=0.29, p=.005), but a reduction of symptoms was observed for
children who received these medications and did have an internalizing diagnosis (ab=-0.50,
p=.004).
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Adherence also served as a mediator of treatment process variable effects on internalizing
symptoms. Better internalizing outcomes were observed for youth who were prescribed alpha-2
agonists and who also had higher parent expectancies (ab=-2.55, p=.001) and higher child
motivation (ab=-2.75, p=.029). This latter effect reflected inconsistent mediation, as the direct
effect of child motivation on internalizing symptom change through adherence was associated
with a worsening of symptoms (c’=0.47, p=.001). Clinician-rated alliance with children was also
indirectly associated through 1-month adherence with a worsening of symptoms for youth who
were prescribed both atypical antipsychotics and alpha-2 agonists (ab=6.31, p=.016).
With regard to the process of influence of attention problems, multiple expectancy and
motivation factors showed an indirect effect on change through alliance. Worsening of
symptoms was predicted by higher child expectancies through child alliance for youth who were
prescribed alpha-2 agonists (ab=0.21, p=.042). Higher parent expectancies were associated with
attention problem exacerbation directly through parent alliance for youth who received
concurrent treatment by 1-month follow-up (ab=0.25, p=.029); however, these symptoms were
inconsistent with direct effect symptom reductions for youth who had medium (c’=-0.53,
p<.001) and high (c’=-1.05, p<.001) intensity levels of side effects. Higher levels of parent
motivation were associated with worsening of attention problems indirectly through child
alliance for youth who were prescribed stimulants (ab=0.05, p=.049) and indirectly thorough
parent alliance for youth who received concurrent treatment by 1-month follow-up (ab=0.39,
p<.001) and who had high levels of functional interference due to side effects (ab=0.30, p=.001).
Parent motivation was also associated with worsening of attention systems indirectly thorough
clinician-rated alliance with parents for youth who had an externalizing diagnosis and did not
receive concurrent treatment by 3-month follow-up (ab=0.32, p=.002).
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The indirect effect of child motivation on attention problems varied depending on
moderators. For youth who were prescribed atypical antipsychotics, increased child motivation
was associated with an increase in attention problems indirectly through parent alliance in youth
with low levels of functional interference due to side effects (ab=0.35, p=.029) and a reduction
in attention problems in youth who had high levels of functional interference due to side effects
(ab=-0.66, p<.001). It was also associated with an indirect reduction of attention problems
through parent alliance for youth who were prescribed antipsychotics and received concurrent
treatment by 1-month follow-up (ab=-0.93, p<.001). For youth who did not receive concurrent
treatment by 3-month follow-up, it was associated through clinician-reported alliance with
parents with an exacerbation of symptoms for youth who were not prescribed atypical
antipsychotics (ab=0.27, p=.015), though this reflected inconsistent mediation relative to the
direct effect (c’=-0.39, p=.037), and also a reduction of symptoms for these youth was observed
when they were prescribed atypical antipsychotics (ab=-0.49, p=.002). Adherence also served as
a mediator of treatment process effects on attention problems, as clinician-rated alliance with
children through 1-month adherence was indirectly associated with an increase in attention
symptoms for youth prescribed atypical antipsychotics and who experienced a high intensity of
side effects (ab=0.63, p=.023).
The pattern of significance in bivariate analyses also resulted in one mediation model that
had 2 mediators in sequence, which is depicted in Figure 2. From this model, child motivation
showed an indirect effect through both clinician-reported alliance with children and adherence at
1-month follow-up; this indirect effect depended on prescription of atypical antipsychotics and
intensity of side effects. For youth with high intensity of side effects, a reduction in attention
problems was observed when youth were not prescribed atypical antipsychotics (abc=-0.12,
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p=.039), but an increase in attention problems was observed when atypical antipsychotics were
prescribed (abc=0.13, p=.015).
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Discussion
The objective of this study was to examine the role of psychosocial variables in pediatric
psychiatric treatment, including pretreatment expectancies, motivation for behavior change,
therapeutic alliance, and medication adherence. It was anticipated that these variables would
have positive relationships with each other and would be associated with symptom reduction.
While the psychosocial variables largely showed positive relationships with each other, there
were some unexpected inverse relationships, and there were many unexpected associations
between psychosocial variables and exacerbated clinical symptoms.
The main theme that encompasses the pattern of observed effects is that they were far
less uniform than is usually reported in common factors literature. Usually, common factors are
construed as single entities that only show positive relationships with each other and treatment
outcome. While this pattern was observed at times, in the present investigation common factors
were observed to function in different manners across populations, reporters, and interventions,
frequently in a counterintuitive manner. These results suggest that common factors are not as
theoretically consistent as is often portrayed in the mental health literature. Or, they may not be
as theoretically consistent in child psychiatry as they are in other behavioral and medical fields.
Psychosocial correlates of treatment outcome are underexplored in primarily psychiatric settings,
which gives little basis for comparison. In pediatric psychotherapy, treatment process variables
have been observed to show differing roles across treatment approaches (Hogue et al., 2006;
Karver et al., 2008), and perhaps their function may differ even more markedly when
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considering psychiatric approaches. It may also be that negative associations with common
factors in other studies are weaker than the positive ones (as was observed in the Shirk et al.,
2011 meta-analysis for child alliance). In this case, these negative effects may exist, but even
then they will be detected and reported less frequently. Given the novel approach of this study
and the preliminary nature of its findings, its major contributions are less focused on individual
findings. Instead, its primary value lies in highlighting that psychosocial variables have a notable
impact on psychopharmacological treatment outcome in children, identifying that their influence
may be much more complicated than is commonly portrayed, and identifying hypotheses for the
origins of this complexity.
Despite the observed inconsistencies, a number of patterns emerged among results that
can be placed in context with prior literature. Regarding exogenous variables, significant
correlations were all observed in the expected positive directions. Of note, the majority of
nonsignificant correlations reflected cross-informant correlations (i.e., nonsignificant correlations
were almost always those between a child-related construct and a parent-related construct). The
only exception to this pattern was the nonsignificant correlation between parental motivation and
parental expectancies. This disagreement across reporters has been well documented in pediatric
mental health research (Martel, Markon, & Smith, 2016) and thus may reflect differences in
reporter perspectives in addition to lack of construct overlap. With regard to expectancies and
motivation, the most consistent correlate was child motivation, as more motivated children also
had higher expectancies and had parents who had higher motivation and expected better
treatment outcome. Child motivation is an underexplored construct, as the majority of motivation
research in child psychopathology focuses on parental motivation. These findings suggest that it
may not only be related to outcomes, but also may serve as a unique indicator of positive ratings
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on other psychosocial constructs. One exception to the observed pattern of correlations was that
that parent motivation and parental expectancies were not significantly correlated. While adult
motivation and expectancies are often related, there are reports of nonsignificant relationships
among the constructs (e.g., Vogel et al., 2006). The magnitude of the observed correlation was
similar to other significant correlations in this study, reflecting an effect of measurement error on
the detection of a significant relationship.
Several patterns also emerged in predictive models, which applied to bivariate
approaches as well as moderated and mediated approaches. A very surprising pattern was the
multiple associations of therapeutic alliance with an increase in symptoms; a common thread
among many of these observations is that such worsening occurred only in the presence of
markers of externalizing behavior (e.g., prescription of medications that are used for
externalizing conditions such as alpha-2 agonists or atypical antipsychotics). Although alliance is
usually associated with improved treatment outcome, with these patients early session alliance
has been associated at times with an increase of symptoms in psychotherapy (Florsheim,
Shotorbani, Guest-Warnick, Barratt, & Hwang, 2000; Hogue, Dauber, Stambaugh, Cecero, &
Liddle, 2006). Others have observed that some of these patients may actually need more clinician
authority and boundary setting early on in the therapeutic relationship (Gallagher, Kurtz, &
Blackwell, 2010). Different therapist engagement behaviors can be differentially effective
depending on the treatment approach (Karver et al., 2008), and youth with externalizing behavior
are an identifiable target population for using modified engagement techniques (Karver &
Caporino, 2010). Additionally, some of these patients may be adept at positive self-presentation
for a limited period of time early in treatment, which may be a marker for poorer outcome
(Florsheim et al., 2000). An ideal therapeutic relationship in early sessions may then differ for
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these patients, as warmth and emotional support may be more appropriate for patients who are
less likely to test clinician boundaries, while an authoritative but empathic early relationship may
set the stage for better outcomes for patients who may be more likely to initiate discord. The
unexpected relationships between alliance and outcome for these patients was also reflected in
observed negative indirect effects, as any positive effects of expectancies/motivation on outcome
were reversed when communicated through a negative relationship between alliance and
outcome. This indirect effect was observed despite positive direct effects at times (e.g., a positive
direct effect of child motivation on symptom reduction), leading to inconsistent mediation. This
pattern of moderation was also seen in prediction of alliance, as alliance more frequently had a
positive relationship with other common factors for patients who did not match the
externalizing/ADHD profile.
Similarly surprising was the frequently negative association between higher expectancies
and treatment outcome. While expectancies have often been associated with positive treatment
outcome, there has been more variability in the relationship between expectancies and treatment
relative to other common factors (Greenberg et al., 2006). In addition, overly high expectancies
can be associated with poorer treatment overcome should treatment response not match these
high standards of expectations (Constantino et al., 2011; Gaitan-Sierra & Hyland, 2015).
Accordingly, clinicians may wish to carefully monitor not only the overall level of expectancies,
but also consider whether they are appropriate given the expected outcomes.
Another unexpected result was the pattern of relationships observed with adherence. A
limited and confounded set of relationships were detected between adherence and other common
factors as well as treatment outcome, as opposed to the uniformly positive associations expected.
Most remarkably, stronger adherence was at times associated with poorer outcomes. However,
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this was generally in the presence of stronger side effects or medications for youth with
externalizing problems, whereas youth with fewer side effects more frequently showed a positive
relationship between stronger adherence and positive treatment outcome. It may be that if
medications are aversive, adhering to them strongly actually does not help outcome and may be
making matters worse in the long run. In this case, monitoring side effects is not just a factor in
premature medication discontinuation (Julius et al., 2009) but is also a possible reason for
suboptimal outcomes, even in patients who are taking medications appropriately. Yet, given the
strong role of adherence in outcome for a number of conditions, it was still unanticipated that
adherence would not be significantly related with outcome or other common factors in many
instances.
Additionally, when considering relationships between other common factors and
adherence, parent expectancies and child motivation were associated with poorer adherence.
Only clinician-rated alliance with children was associated with better medication adherence, and
in this case only for youth who were prescribed atypical antipsychotics. While overly optimistic
expectancies may have the same deleterious effects on adherence as they can on outcome, the
relationship between adherence and motivation cannot be explained in the same fashion. Of note,
motivation was assessed in the context of motivation for making personal changes in
symptomology, not motivation for adherence (which at times has been considered a separate
construct; Touré-Tillery & Fishbach, 2014). Children who may be looking to make active
behavioral steps toward change may eventually get there, but may find medications to be a less
active means to achieve this end (as has been seen in some patient preference studies; e.g.,
Angelo, Miller, Zoellner, & Feeny, 2008). Given that child motivation was also related to parent
expectancies, children who are more motivated to make active changes themselves may have
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parents who are overly expectant of change. Moreover, they may also function better with more
active methods of change, and may find a pharmacologically-based intervention to be
inconsistent with their preferred approach to change.
In contrast to these unpredicted findings, child motivation was more frequently associated
with symptom improvement. This is more consistent with the overall common factors literature.
In some ways, motivation differs from other common factors with reference to theoretical
relationships with treatment outcome and patterns of moderation. Unlike expectancies,
motivation is unlikely to show negative effects on outcome when it is too high. Motivation
differs from alliance with regard to moderation, as the nature of an appropriate alliance may
differ across internalizing and externalizing populations (Zorzella, Muller, & Cribbie, 2015),
whereas the function of motivation is more stable across these groups. For instance, pure warmth
for an internalizing patient may serve as enabling for an externalizing patient, whereas the nature
of patient motivation does not vary in this between-population manner. Instead, withinpopulation variability is more likely to differ across disorders, as internalizing patients are more
often self-referring for treatment and less likely to show poor motivation for change (e.g., Duhig
& Phares, 2003). Less within-population variability would also be expected for parents, given
that they are frequently the ones who make the decision about whether to initiate child treatment
(Nock & Kazdin, 2001). Thus by default parents have motivation for child behavior change,
leaving more room for variability in children. This decreased variability in parental motivation
may reduce the ability to predict outcomes of interest. Given these facets of parent and child
motivation, child motivation appears to be a common factor that is uniquely indicative of future
symptom reduction, compared to parent motivation which is less variable.
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Notably, several hypothesized moderators did not significantly interact with main effects.
In particular, significant moderation was not observed for child age and for variables associated
with internalizing and neurodevelopmental disorders (including clinician diagnoses of these
conditions and prescription of SRIs). While nonsignificance does not mean that these variables
do not have an effect on observed relationships, and post-hoc correction reduces the power to
detect their specific influence, it does reflect that they had a lesser influence on the common
factors process relative to other moderators. It may be that common factors show a more
consistent effect in the presence of these constructs. While there have been some suggestions of
developmental differences in the presentation of therapeutic alliance in particular (Shirk,
Caporino, & Karver, 2010), the nature of common factors may vary more substantially among
youth who are less likely to desire treatment themselves (i.e., children with
disruptive/externalizing problems). Frequency of side effects also did not significantly moderate
outcomes, while intensity and functional interference associated with side effects were
significant moderators. Frequency of symptoms has a different and possibly more limited
relationship with mental health symptoms than intensity and functional interference, as patients
may have one especially impairing symptom which is very bothersome, or conversely may
experience multiple low level symptoms that in aggregate are not very bothersome (Jones et al.,
2013). Often in these cases overall symptom severity (as rated by perceived intensity and/or
interference) is of greater importance.
With regard to overall magnitude of findings, most significant results in bivariate
analyses were in the medium range, which is consistent with meta-analytic estimates of common
factors in psychotherapy. Several standardized indirect effects also particularly stood out relative
to the others (larger than 2), all of which involved the role of 1-month adherence for youth who
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were prescribed alpha-2 agonists and the associated effects on internalizing symptoms. The
strong effect of this b path was the common element among these indirect effects. It may be that
effects of adherence are particularly pronounced for youth taking alpha-2 agonists, where in this
instance increased adherence was associated with worsening of internalizing symptoms. Alpha-2
agonists were notable among study medications in that they have uniquely strong effects of acute
withdrawal, as rebound hypertension and distress can occur within even one day of sudden
discontinuation (particularly with clonidine; Giovannitti, Thoms, & Crawford, 2015). The
distribution of adherence in study participants approximated bimodality, especially for poor
adherence; that is, patients who had low adherence had generally stopped prescribed medications
altogether, while patients who took medication showed more variability in adherence. While
strong but imperfect adherence may be adequate for many medications, required adherence
levels may be even higher for alpha-2 agonists, and inconsistent adherence to these medications
may be associated with an increase in internal emotional distress. Standard errors for these
estimates were fairly large as well, resulting in p-values that were not as small as many other
significant effects observed. Given this, the size of these indirect estimates may have been
affected in part by instability associated with the relatively relative small sample size of youth
prescribed alpha-2 agonists in the present sample.
As a whole, the observed patterns of results (and their exceptions) merit replication and
evaluation in future research. As such, it is premature to make strong and conclusive inferences
from individual findings, but rather the present models suggest new hypotheses that have often
not been considered in common factors research (e.g., alliance being associated with increases in
symptoms under some conditions, common factors having heterogeneous effects across
conditions and interventions). Additional possible reasons for the observed exceptions could
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include confounding variables that were unaccounted for (Moore, Neugebauer, van der Laan, &
Tager, 2012). For instance, there is some evidence of reciprocal influence of alliance and
symptom change in pediatric psychological treatment (Labouliere, Reyes, Shirk, & Karver,
2015) and this longitudinal influence may confound results observed at 3 months after treatment
initiation. Oppositional youths in particular may show more instability in the therapeutic
relationship throughout the course of treatment (Rauktis, Vides de Andrade, Doucette,
McDonough, & Reinhart, 2005). While initial status of psychosocial variables frequently has a
substantial influence on subsequent treatment outcome, perhaps consideration of their continued
role throughout treatment can serve to further explain the observed results in future research.
This concept would be reflected in part by the relative lack of prediction of 3-month adherence
relative to the more robust set of associations with 1-month adherence. Perhaps pretreatment
common factors are more strongly related to more proximal outcomes and as the outcomes
become increasingly distal, changes in psychosocial variables show a more dynamic influence
(e.g., alliance ruptures; Safran & Kraus, 2014).
Several limitations of this study are to be noted. First, there were missing data at all time
points, with a substantial amount of missing data at follow-up timepoints in particular. Multiple
efforts were made to address this missingness that have been shown to produce substantial
improvement in parameter estimation in real-world research (e.g., FIML estimation, including
auxiliary covariates that are predictive of missingness). Such methods can produce estimates that
match population parameters. These missing data were a trade-off for obtaining a naturalistic
sample that resembles treatment-seeking patients from a variety of backgrounds. Other studies
with real-world populations have been successfully conducted with even higher levels of missing
data by using similar analytical approaches (Dong & Peng, 2013). Second, given that inclusion
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criteria were very broad with treatment-seeking patients, there is substantial heterogeneity in
psychopathology and psychopharmacology among participants. Common factors have generally
been seen to have influence across populations, but rarely are they evaluated in a sample that is
representative of such a broad set of problems. This broad sample permitted comparisons of the
role of common factors across these populations and allowed for the generation of a number of
unforeseen findings, which would be not be possible with more limited inclusion criteria.
Nevertheless, this heterogeneity, along with lack of randomization, precludes the identification
of causal mechanisms and a priori evaluation of differences across populations. This study is a
first step towards evaluating the role of multiple psychosocial variables in tandem with
psychopharmacological intervention, and as such serves as both a test of prior hypotheses and as
a means to generate new ones for further investigation. Third, measurement of symptom change
was restricted to self-report, and there was not a single best outcome measure for each patient.
Future work would benefit from independent evaluation of diagnosis and symptom severity.
With multiple measures of outcome (i.e., externalizing, internalizing, attention problems), this
study is able to capture the different targets of treatment relevant to each patient. One concern
about using these multiple measures of outcome is that symptom measurements were included
for non-principal treatment targets (e.g., measuring internalizing symptoms in a child with
ADHD and few internalizing problems). While the analytic models employed adjust estimates
for pre-treatment scores, this process can serve to reduce the average magnitude of change.
However, there were many participants with externalizing, internalizing, and attention problem
symptoms, providing sufficient variability to evaluate symptom change outcomes for these
domains. This method is consistent with other studies in pediatric psychopathology, which
frequently eschew a single total combined total score and rather divide behavior problems into
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subgroups such as internalizing and externalizing symptoms (Lindhiem, Bennett, Orimoto, &
Kolko, 2016). Symptom increases in non-principal treatment targets are also possible and often
are overlooked in clinical work, and this multi-domain approach to outcome measurement
permitted evaluation of this hypothesis. Finally, a large number of hypothesis tests were
performed. Post-hoc hypotheses involving moderators were controlled using strong post-hoc
corrections, but the chance for Type I error still remains.
Clinically, these results suggest that common factors impact treatment outcome, even in
psychopharmacological interventions. While they show notable influence across a number of
populations, their impact may not be as straightforward as is often portrayed. There may not be a
single “optimal patient” who receives better outcomes due to intrinsic motivation, a positive
outlook towards treatment, and strong alliance with the clinician. In fact, being too strong in
some of these areas may actually attenuate outcome in some circumstances. Moreover, the
process of how these factors work concurrently throughout treatment may also be
counterintuitive at times. Changes in the function of common factors during the full course of
treatment has also been seen in psychotherapy; for example, early alliance may be facilitated by
warmth and empathy, whereas alliance later on in treatment may be better developed by
directiveness for patients who are looking for continued change (Keijsers et al., 1995). For these
reasons, careful monitoring of both the level and specific role of common factors throughout
treatment is warranted. One option to implement this type monitoring is through brief
assessments in therapy progress notes (De Nadai et al., 2017). In pediatric interventions, the
presence of multiple therapeutic stakeholders means this monitoring involves several
dimensions, as parents, children, and clinicians often do not agree on common factors (e.g.,
Bickman et al., 2012). Monitoring of therapeutic alliance for children with ADHD and
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externalizing disorders may deserve special focus. A positive initial alliance can be associated
with poorer long-term outcomes for these patients, which is contrary to conventional wisdom.
Theoretically, these results suggest that psychosocial variables serve as common factors
across patient populations and treatment interventions in pediatric psychiatry, but the nature of
their influence on outcome may not be as common as originally thought. They are generally
considered to have a consistently positive impact on symptom outcome and are conceptualized in
this manner across all symptom types and patient populations. While not frequently considered,
possible symptom exacerbations based on psychological interventions have been overlooked
(Barlow, 2010). Not only are the effects of psychosocial variables not uniformly common across
situations, but they may not be common across reporters as well. Contradictory effects were
observed at times depending on the reporter in the present sample. Reporting agreement in child
mental health treatment is often highly variable further examination among reporter agreement
and discrepancies may provide further insight (De Los Reyes et al., 2015). Methods that unify
the input of multiple reporting parties such as the Alliance Observational Coding System
(AOCS, Karver, Shirk, Day, Field, & Handelsman, 2003) or factor analytic modeling (Bauer et
al., 2013) may also provide novel insight regarding how common factors function within child
common factors research.
Results from this investigation suggest that the process of how common factors work
together can lead to unexpected changes in results. Many investigations focus on the early
session role of common factors or aggregate measures of common factors throughout treatment,
and rarely do they go beyond bivariate associations with outcome. Given how the function of
psychosocial variables can change throughout treatment, continual measurement of these
variables in clinical investigations may be necessary to elucidate their effects. For example,
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interpersonal processes between clinician and patient have predicted subsequent outcome
expectancies even when controlling for baseline differences in expectancies (Ahmed, Westra,
and Constantino, 2012), and dyadic reciprocity in alliance has been observed in adult patients
(Marcus, Kashy, Wintersteen, & Diamond, 2011). How common factors vary among each other
and across time will be necessary to understand their role in treatment outcome.
Overall, the impact of psychosocial variables spans across pediatric psychiatric
treatments, but may not function in a “one size fits all” fashion across different therapeutic
populations and approaches. The present findings suggest that the process of how common
factors work in pediatric psychiatry may be much more complicated than is often suggested.
Psychosocial variables can cut across treatments as elements that are common to all psychiatric
interventions, but the nature of their effects on outcome may actually not be common. Careful
consideration of the differences in roles of psychosocial variables across patient populations and
interventions may help to better explain treatment effects in clinical and research settings, with
particular focus on how they are impacting treatment for both better and worse.
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Tables and Figures
Table 1. Timetable of self-report assessments administered
Baseline
Parent
Parent Alliance (WAI-SF)
Parent Expectancy (CEQ-P)
Parent Motivation (URICA-P)
Parent-Reported Adherence (BMQ)
Parent-Rated Symptoms (CBCL)
Parent-Reported Outcome (BPM-P)
Parent Report of Services (SACA)
Parent-Rated Side Effects (FIBSER/PRISE)
Youth
Youth Alliance (TASC-R)
Youth Expectancy (CEQ-C)
Youth Motivation (URICA-C)
Youth Anxiety and Depression (MASC-ADI/CDI-2-SF)a

M1

M3

X
X
X
X
X
X
X
X

X
X

X
X
X
X

Youth Symptoms (YSR)a
Clinician
Clinician Alliance (TAQ-R)
X
Note. M1=1-month follow-up; M3=3-month follow-up; WAI-SF=Working Alliance InventoryShort Form; CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; URICA-P=
University of Rhode Island Change Assessment-Parent Version; BMQ=Brief Medication
Questionnaire; CBCL=Child Behavior Checklist; BPM-P=Brief Progress Monitor-Parent
Version; SACA= Service Assessment for Children and Adolescents; FIBSER=Frequency,
Intensity, and Burden of Side Effects Rating; PRISE=Patient Rated Inventory of Side Effects;
TASC-R=Therapeutic Alliance Scale for Children-Revised; CEQ-C=Credibility/Expectancy
Questionnaire-Child Version; URICA-C= University of Rhode Island Change Assessment-Child
Version; MASC-ADI=Multidimensional Anxiety Scale for Children-Anxiety Disorders Index;
CDI-2-SF=Children’s Depression Inventory-2nd Edition Short Form;
YSR=Youth Self Report; TAQ-R=Therapeutic Alliance Quality Rating
a

The MASC-ADI and CDI-2-SF were administered to 21 participants who had anxiety and/or
depression diagnoses; all other participants received the YSR
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Table 2. Descriptive statistics for the present sample
Mean
16.62
17.16
7.70
10.36
37.77
71.61
3.57
3.98
14.50
5.95
15.98
16.43
20.76
21.19
70.25
68.14
2.33
1.98
1.33
5.81
5.16
4.52
5.06
6.86
5.98

Variable
CEQ-C
CEQ-P
URICA-C
URICA-P
TASC-R
WAI-SF
TAQ-R-Child
TAQ-R-Parent
MASC-ADIa
CDI-2-SFa
CBCL Externalizing
CBCL Internalizing
YSR Externalizinga
YSR Internalizinga
BMQ (M1)
BMQ (M3)
FIBSER-Frequency
FIBSER-Intensity
FIBSER-Interference
BPM-P Externalizing (Baseline)
BPM-P Externalizing (M3)
BPM-P Internalizing (Baseline)
BPM-P Internalizing (M3)
BPM-P Attention Problems (Baseline)
BPM-P Attention Problems (M3)

SD
5.94
4.83
2.58
1.29
6.94
9.67
0.70
0.68
6.21
3.76
10.80
9.39
9.50
11.75
42.15
44.47
2.25
1.67
1.52
3.47
3.58
2.92
3.28
3.25
3.37

Alpha
.84
.85
.87
.71
.86
.90
N/A
N/A
.75
.74
.92
.87
.88
.90
N/Ab
N/Ab
N/Ab
N/Ab
N/Ab
.82
.86
.76
.81
.81
.83

Note. M1=1-month follow-up; M3=3-month follow-up; CEQ-C=Credibility/Expectancy QuestionnaireChild Version; CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; URICA-C= University of
Rhode Island Change Assessment-Child Version; URICA-P= University of Rhode Island Change
Assessment-Parent Version; TASC-R=Therapeutic Alliance Scale for Children-Revised; WAISF=Working Alliance Inventory-Short Form; TAQ-R=Therapeutic Alliance Quality Rating; MASCADI=Multidimensional Anxiety Scale for Children-Anxiety Disorders Index; CDI-2-SF=Children’s
Depression Inventory-2nd Edition Short Form; CBCL=Child Behavior Checklist; YSR=Youth Self
Report; BMQ=Brief Medication Questionnaire; FIBSER=Frequency, Intensity, and Burden of Side
Effects Rating; BPM-P=Brief Progress Monitor-Parent Version
a

The MASC-ADI and CDI-2-SF were administered to 21 participants who had anxiety and/or depression
diagnoses; all other participants received the YSR
b

Cronbach’s alpha could not be calculated for this measure because only one item is used to create the
total score
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Table 3. Bivariate correlations among psychosocial variables
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

1. CEQ-C

-

0.07

0.03

0.27**

0.11

0.08

0.10

-0.08

-0.12

0.06

0.11

0.16

0.12

-0.16

0.10

-0.02

-0.09

0.05

2. CEQ-P

-

-

0.16*

0.17

0.22*

0.13

0.04

-0.30

-0.26**

-0.24

-0.33**

-0.32**

-0.10

0.05

-0.09

-0.20

-0.10

-0.32**

3. URICA-C

-

-

-

0.23**

0.49**

-0.05

0.21*

0.19*

-0.24

0.03

0.03

-0.11

-0.02

-0.09

0.18*

-0.06

-0.13

0.34**

-0.19

4. URICA-P

-

-

-

-

0.06

0.30**

-0.06

0.14*

0.22

0.11

0.08

0.25

0.29**

0.08

0.18*

-0.04

0.09

0.12

0.02

5. TASC-R

-

-

-

-

-

6. WAI-SF

-

-

-

-

-

7. TAQ-R-C

-

-

-

-

8. TAQ-R-P

-

-

-

9. BMQ (M1)

-

-

10. BMQ (M3)

-

11. FIBSER-1

0.34**

0.17

-0.01

0.47**

0.12

-0.07

0.10

0.08

-0.21*

-0.34**

-0.07

-0.18**

0.05

-0.13

-0.23*

-0.11

-

0.01

0.26**

0.00

-0.03

0.08

0.15

0.31**

0.02

0.08

0.05

0.11

0.10

0.17

-

-

-

0.26**

-0.09

-0.10

0.29*

-0.07

-0.17

-0.26*

-0.09

-0.14

-0.03

-0.08

-0.02

-

-

-

-

-

0.09

-0.02

0.08

0.06

0.08

-0.23*

0.02

0.01

-0.15

0.03

0.07

-

-

-

-

-

-

-

0.55**

-

-

-

-

-

-

-

-

-

0.09

0.05

0.10

0.04

-0.01

-0.04

-0.06

-0.12

-0.03

-

-

-

-

-

-

-

-

-

-

-

0.79**

0.53**

-0.09

-0.02

0.01

0.13

-0.21**

0.22*

12. FIBSER-2

-

-

-

-

-

-

-

-

-

-

-

-

0.80**

-0.05

0.08

-0.03

0.19

-0.07

0.27*

13. FIBSER-3

-

-

-

-

-

-

-

-

-

-

-

-

-

0.23*

0.12

0.16

0.43**

0.10

0.41**

14. BPM-P Ext (B)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.07

0.48**

0.70**

0.02

0.32**

15. BPM-P Int (B)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.22*

-0.05

0.60**

-0.05

16. BPM-P Att (B)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.50**

-0.06

0.72**

17. BPM-P Ext (M3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.17

0.62**

18. BPM-P Int (M3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.13

19. BPM-P Att (M3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.24

0.30

0.11

-0.14

-0.20

-0.06

0.04

-0.17

Note.* p<.05, ** p<.01
Note. B=Baseline; M1=1-month follow-up; M3=3-month follow-up; CEQ-C=Credibility/Expectancy Questionnaire-Child Version;
CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; URICA-C= University of Rhode Island Change Assessment-Child
Version; URICA-P= University of Rhode Island Change Assessment-Parent Version; TASC-R=Therapeutic Alliance Scale for
Children-Revised; WAI-SF=Working Alliance Inventory-Short Form; TAQ-R-C=Therapeutic Alliance Quality Rating-Child Version;
TAQ-R-P=Therapeutic Alliance Quality Rating-Parent Version; BMQ=Brief Medication Questionnaire; FIBSER-1=Frequency,
Intensity, and Burden of Side Effects Rating-Item 1 (Frequency); FIBSER-2=Frequency, Intensity, and Burden of Side Effects Rating60

-0.04

Item 2 (Intensity); FIBSER-3=Frequency, Intensity, and Burden of Side Effects Rating-Item 3 (Interference); BPM-P Ext=Brief
Progress Monitor-Parent Version (Externalizing); BPM-P Int=Brief Progress Monitor-Parent Version (Internalizing); BPM-P
Att=Brief Progress Monitor-Parent Version (Attention Problems)
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Table 4. Residualized regression relationships for all main effects and significant moderators of main effects

Moderator

a

Moderator
Levelb

b (Slope)c
0.28**
0.31**
-0.02**
0.62**
0.18
1.03**
0.36**
-0.32

R2d
0.08
0.16
0.16
0.15
0.15
0.26
0.26
0.26

DV
TASC-R
TASC-R
TASC-R
TASC-R
TASC-R
TASC-R
TASC-R
TASC-R

Predictor
CEQ-C
CEQ-C
CEQ-C
CEQ-C
CEQ-C
CEQ-C
CEQ-C
CEQ-C

TASC-R

CEQ-P

0.18

0.03

TASC-R

URICA-C

0.52**

0.24

TASC-R
TASC-R
TASC-R
TASC-R
TASC-R

URICA-P
URICA-P
URICA-P
URICA-P
URICA-P

WAI-SF

Alpha-2
Alpha-2
ADHD
ADHD
FIBSER-2
FIBSER-2
FIBSER-2

Low
High
Low
High
Low
Med
High

0.07
-0.26*
0.18*
0.16
-0.01*

0.01
0.12
0.12
0.04
0.04

CEQ-C

0.11

0.01

WAI-SF

CEQ-P

0.22*

0.05

WAI-SF
WAI-SF
WAI-SF

URICA-C
URICA-C
URICA-C

-0.05
-0.01
-0.21**

0.00
0.05
0.05

WAI-SF

URICA-P

0.30**

0.09

TAQ-R-C

CEQ-C

0.08

0.01

TAQ-R-C

CEQ-P

0.13

0.02

TAQ-R-C

URICA-C

0.21*

0.04

TAQ-R-C

URICA-P

TAQ-R-P

CEQ-C

CTM3
CTM3
Stimulant
Stimulant

Low
High
Low
High

Atypical
Atypical

Low
High
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-0.06

0.00

0.11

0.01

Table 4. (continued)
Moderator
Levelb

b (Slope)c
0.04

R2d
0.00

Low
High

0.20**
0.27**
0.03**

0.04
0.09
0.09

Low
High

0.14*
-0.22*
0.22**

0.02
0.10
0.10

CEQ-C

-0.15

0.03

BMQ (M1)

CEQ-P

-0.34**

0.11

BMQ (M1)

URICA-C

-0.28*

0.07

BMQ (M1)

URICA-P

0.26

0.07

BMQ (M1)

TASC-R

-0.02

0.00

BMQ (M1)

WAI-SF

0.00

0.00

BMQ (M1)
BMQ (M1)
BMQ (M1)

TAQ-R-C
TAQ-R-C
TAQ-R-C

BMQ (M1)

TAQ-R-P

BMQ (M3)

DV
TAQ-R-P

Predictor
CEQ-P

TAQ-R-P
TAQ-R-P
TAQ-R-P

URICA-C
URICA-C
URICA-C

TAQ-R-P
TAQ-R-P
TAQ-R-P

URICA-P
URICA-P
URICA-P

BMQ (M1)

Moderatora

Atypical
Atypical

Ext Dx
Ext Dx

Atypical
Atypical

Low
High

-0.03
-0.07
0.14**

0.00
0.05
0.05

0.12

0.02

CEQ-C

-0.11

0.03

BMQ (M3)

CEQ-P

-0.19*

0.05

BMQ (M3)

URICA-C

-0.03

0.02

BMQ (M3)

URICA-P

-0.05

0.02

BMQ (M3)

TASC-R

0.06

0.02

BMQ (M3)

WAI-SF

-0.15

0.04

63

Table 4. (continued)
Moderator

a

Moderator
Levelb

b (Slope)c
0.04

R2d
0.02

DV
BMQ (M3)

Predictor
TAQ-R-C

BMQ (M3)

TAQ-R-P

0.00

0.02

BPM-P Ext
BPM-P Ext
BPM-P Ext

CEQ-C
CEQ-C
CEQ-C

-0.10
-0.18
0.04*

0.01
0.06
0.06

BPM-P Ext

CEQ-P

-0.14

0.02

BPM-P Ext
BPM-P Ext
BPM-P Ext

URICA-C
URICA-C
URICA-C

-0.05
-0.16
0.14**

0.00
0.09
0.09

BPM-P Ext

URICA-P

0.03

0.00

BPM-P Ext

TASC-R

-0.07

0.01

BPM-P Ext
BPM-P Ext
BPM-P Ext

WAI-SF
WAI-SF
WAI-SF

0.08
0.40**
-0.02

0.01
0.03
0.03

BPM-P Ext

TAQ-R-C

0.15

0.02

BPM-P Ext

TAQ-R-P

0.01

0.00

BPM-P Ext

BMQ (M1)

0.05

0.01

BPM-P Ext

BMQ (M3)

-0.06

0.01

BPM-P Int
BPM-P Int
BPM-P Int

CEQ-C
CEQ-C
CEQ-C

0.00
-0.04
0.13**

0.00
0.04
0.04

BPM-P Int

CEQ-P

-0.14

0.02

BPM-P Int

URICA-C

Tic Dx
Tic Dx

Low
High

Tic Dx
Tic Dx

Low
High

Ext Dx
Ext Dx

Low
High

Atypical
Atypical

Low
High

0.27**
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0.06

Table 4. (continued)
DV
BPM-P Int
BPM-P Int
BPM-P Int

Predictor
URICA-P
URICA-P
URICA-P

BPM-P Int
BPM-P Int
BPM-P Int

TASC-R
TASC-R
TASC-R

BPM-P Int

WAI-SF

BPM-P Int

Moderator

a

No Prescription
No Prescription

Atypical
Atypical

Moderator
Levelb
Low
High

b (Slope)c
0.01
-0.18*
0.08**

R2d
0.00
0.04
0.04

Low
High

-0.13
-0.22*
0.03**

0.02
0.09
0.09

0.05

0.00

TAQ-R-C

-0.03

0.00

BPM-P Int
BPM-P Int
BPM-P Int

TAQ-R-P
TAQ-R-P
TAQ-R-P

Low
High

0.01
0.05
-0.20**

0.00
0.06
0.06

BPM-P Int
BPM-P Int
BPM-P Int

BMQ (M1)
BMQ (M1)
BMQ (M1)

Low
High

-0.18
-0.18
0.83**

0.03
0.07
0.07

BPM-P Int

BMQ (M3)

-0.11

0.01

BPM-P Att

CEQ-C

-0.03

0.00

BPM-P Att
BPM-P Att
BPM-P Att
BPM-P Att

CEQ-P
CEQ-P
CEQ-P
CEQ-P

-0.27*
0.29
-0.24**
-0.77**

0.07
0.18
0.18
0.18

BPM-P Att

URICA-C

-0.16

0.02

BPM-P Att

URICA-P

0.05

0.00

BPM-P Att

TASC-R

-0.15*

0.02

Atypical
Atypical

Alpha-2
Alpha-2

FIBSER-2
FIBSER-2
FIBSER-2
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Low
Med
High

Table 4. (continued)
Moderator

DV
BPM-P Att
BPM-P Att
BPM-P Att
BPM-P Att
BPM-P Att
BPM-P Att

Predictor
WAI-SF
WAI-SF
WAI-SF
WAI-SF
WAI-SF
WAI-SF

BPM-P Att

TAQ-R-C

BPM-P Att
BPM-P Att
BPM-P Att

TAQ-R-P
TAQ-R-P
TAQ-R-P

CTM3
CTM3

BPM-P Att
BPM-P Att
BPM-P Att
BPM-P Att

BMQ (M1)
BMQ (M1)
BMQ (M1)
BMQ (M1)

FIBSER-2
FIBSER-2
FIBSER-2

a

FIBSER-3
FIBSER-3
FIBSER-3
CTM1
CTM1

BPM-P Att
BMQ (M3)
Note.* p<.05, ** p<.01

Moderator
Levelb
Low
Med
High
Low
High

b (Slope)c
0.14
-0.54**
0.11
0.75**
-0.10
0.35**

R2d
0.02
0.20
0.20
0.20
0.16
0.16

0.07

0.01

Low
High

0.06
0.42**
0.02

0.00
0.04
0.04

Low
Med
High

0.08
-0.49*
0.06
0.61**

0.01
0.17
0.17
0.17

-0.09

0.01

Note. M1=1-month follow-up; M3=3-month follow-up; TASC-R=Therapeutic Alliance Scale for
Children-Revised; WAI-SF=Working Alliance Inventory-Short Form; TAQ-R-C=Therapeutic
Alliance Quality Rating-Child Version; TAQ-R-P=Therapeutic Alliance Quality Rating-Parent
Version; BMQ=Brief Medication Questionnaire; BPM-P Ext=Brief Progress Monitor-Parent
Version (Externalizing); BPM-P Int=Brief Progress Monitor-Parent Version (Internalizing);
BPM-P Att=Brief Progress Monitor-Parent Version (Attention Problems); CEQC=Credibility/Expectancy Questionnaire-Child Version; CEQ-P=Credibility/Expectancy
Questionnaire-Parent Version; URICA-C= University of Rhode Island Change AssessmentChild Version; URICA-P= University of Rhode Island Change Assessment-Parent Version;
TASC-R=Therapeutic Alliance Scale for Children-Revised; WAI-SF=Working Alliance
Inventory-Short Form; TAQ-R-C=Therapeutic Alliance Quality Rating-Child Version; TAQ-RP=Therapeutic Alliance Quality Rating-Parent Version; BMQ=Brief Medication
Questionnaire;Alpha-2=Alpha-2 agonists; FIBSER-2=Frequency, Intensity, and Burden of Side
Effects Rating-Item 2 (Intensity); CTM1=Concurrent treatment received by 1-month follow-up;
CTM3=Concurrent treatment received by 3-month follow-up; Atypical=Atypical antipsychotic;
Ext Dx=Externalizing Diagnosis; Tic Dx=Tic Disorder Diagnosis; FIBSER-3=Frequency,
Intensity, and Burden of Side Effects Rating-Item 3 (Interference)
a

Moderators were included in table if they were significant after Holm-Bonferroni correction
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Table 4. (continued)
b

For continuous moderators, low, medium, high values reflect -1 SD, the mean, and +1 SD
respectively for the corresponding measure. For dichotomous moderators, low values reflect the
absence of the moderator (i.e., 0 in dummy-coding), and high values reflect presence of the
moderator (i.e., 1 in dummy-coding).
c

Slopes reflect standardized beta weights for main effects and standardized simple slopes for
moderators evaluated at the respective moderator level. Significance was evaluated based on
unstandardized analyses as recommended by Fairchild and McQuillin (2010), and standardized
results are presented to facilitate comparison across models.
d 2

R values reflect amount of variance attributable specifically to the predictor in main effect
models, and reflect the amount of additional variance attributable to adding the moderator and its
interaction term in moderation models
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Table 5. Numerical results for indirect effect models tested

Wa
Va
X
M
Y
Expectancies/Motivation Through Alliance to Outcome
CEQ-C
TASC-R
BPM-P Att ADHD

Ua

Std.
Indirect
Effectc

Std.
Direct
Effectc

Std.
Total
Effectc

Low W
High W

-0.13
-0.01

0.00
0.00

-0.13
-0.01

Moderator Levelb

CEQ-C

TASC-R

BPM-P Att

Alpha-2

Low W
High W

-0.06
0.21*

0.01
0.01

-0.05
0.22

CEQ-C

TASC-R

BPM-P Att

FIBSER-2

Low W
Med W
High W

-0.17
-0.08
0.01

0.03
0.03
0.03

-0.14
-0.05
0.04

URICA-C

TASC-R

BPM-P Att

-0.07

-0.18

-0.24

URICA-P

TASC-R

BPM-P Att

CTM3

Low W
High W

0.05
-0.07

0.09
0.09

0.14
0.02

URICA-P

TASC-R

BPM-P Att

Stimulant

Low W
High W

-0.04
0.05*

0.08
0.08

0.04
0.14

CEQ-P

WAI-SF

BPM-P Att

0.01
0.25*
0.01
0.25*
0.01
0.25*

-0.01
-0.01
-0.53**
-0.53**
-1.05**
-1.05**

0.00
0.25
-0.52**
-0.27
-1.04**
-0.79*

CTM1

FIBSER-2
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Low V, Low U
High V, Low U
Low V, Med U
High V, Med U
Low V, High U
High V, High U

Table 5. (continued)

Ua

Std.
Direct
Effectc
0.07
0.07

Std.
Total
Effectc
0.03
0.46**

X
URICA-P

M
WAI-SF

Y
BPM-P Att

Wa

Va
CTM1

URICA-C

WAI-SF

BPM-P Att

Atypical

CTM1

Low W, Low V
High W, Low V
Low W, High V
High W, High V

0.00
0.06
-0.04
-0.93**

-0.19
-0.19
-0.19
-0.19

-0.19
-0.13
-0.23
-1.13**

URICA-P

WAI-SF

BPM-P Att

FIBSER-3

Low V
Med V
High V

-0.16
0.07
0.30**

0.01
0.01
0.01

-0.15
0.08
0.31

URICA-C

WAI-SF

BPM-P Att

Atypical

FIBSER-3

Low W, Low V
High W, Low V
Low W, Med V
High W, Med V
Low W, High V
High W, High V

0.01
0.35*
0.00
-0.16
-0.02
-0.66**

-0.21
-0.21
-0.21
-0.21
-0.21
-0.21

-0.20
0.14
-0.21
-0.37
-0.23
-0.87**

URICA-C

TAQ-R-P

BPM-P Att

Atypical

CTM3

Low W, Low V
High W, Low V
Low W, High V
High W, High V

0.27*
-0.49**
0.00
-0.01

-0.39*
-0.39*
-0.39*
-0.39*

-0.13
-0.88**
-0.39*
-0.40
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Moderator Levelb
Low W
High W

Std.
Indirect
Effectc
-0.04
0.39**

Table 5. (continued)

Wa
Ext Dx

Va
CTM3

Ua

Moderator Levelb
Low W, Low V
High W, Low V
Low W, High V
High W, High V

Std.
Indirect
Effectc
-0.18
0.32**
0.04
-0.07

Std.
Direct
Effectc
0.23
0.23
0.23
0.23

Std.
Total
Effectc
0.05
0.54**
0.27
0.15

X
URICA-P

M
TAQ-R-P

Y
BPM-P Att

CEQ-P

WAI-SF

BPM-P Ext

Ext Dx

Low V
High V

0.18
-0.04

-0.51**
-0.51**

-0.32
-0.54**

URICA-P

WAI-SF

BPM-P Ext

Ext Dx

Low V
High V

0.18*
-0.05

-0.09
-0.09

0.09
-0.14

URICA-C

WAI-SF

BPM-P Ext

Atypical

Ext Dx

Tic Dx

Low W, Low V, Low U
Low W, Low V, High U
Low W, High V, Low U
Low W, High V, High U
High W, Low V, Low U
High W, Low V, High U
High W, High V, Low U
High W, High V, High U

-0.01
-0.01
0.00
0.00
-0.48*
-0.48*
0.21
0.21

-0.39*
1.11**
-0.39*
1.11**
-0.39*
1.11**
-0.39*
1.11**

-0.39
1.11**
-0.38
1.12**
-0.86**
0.64
-0.18
1.32**

CEQ-C

TASC-R

BPM-P Int

ADHD

Atypical

Atypical

Low W, Low V and U
High W, Low V and U
Low W, High V and U
High W, High V and U

-0.19
-0.02
0.59**
0.05

0.06
0.06
0.46**
0.46**

-0.13
0.04
1.05**
0.51*
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Table 5. (continued)

X
CEQ-C

M
TASC-R

Y
BPM-P Int

Wa
Alpha-2

Va
Atypical

Ua
Atypical

Moderator Levelb
Low W, Low V and U
High W, Low V and U
Low W, High V and U
High W, High V and U

Std.
Indirect
Effectc
-0.07
0.26*
0.28*
-0.96

CEQ-C

TASC-R

BPM-P Int

FIBSER-2

Atypical

Atypical

Low W, Low V and U
Med W, Low V and U
High W, Low V and U
Low W, High V and U
Med W, High V and U
High W, High V and U

-0.24*
-0.11*
0.03
0.80*
0.36*
-0.09

-0.03
-0.03
-0.03
0.53**
0.53**
0.53**

-0.27**
-0.14*
0.00
1.34**
0.89**
0.45*

URICA-C

TASC-R

BPM-P Int

Atypical

Low V
High V

-0.31**
0.30

0.57**
0.57**

0.26*
0.87**

URICA-P

TASC-R

BPM-P Int

CTM3

Atypical

Low W, Low V
High W, Low V
Low W, High V
High W, High V

0.05
-0.05
-0.22
0.23

0.05
0.05
0.05
0.05

0.10
-0.01
-0.17
0.28

URICA-P

TASC-R

BPM-P Int

Stimulant

Atypical

Low W, Low V
High W, Low V
Low W, High V
High W, High V

-0.05
0.07
0.15
-0.24

0.05
0.05
0.05
0.05

-0.01
0.10
0.19
-0.21
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Std.
Direct
Effectc
-0.02
-0.02
0.56**
0.56**

Std.
Total
Effectc
-0.09
0.24
0.83**
-0.40

Table 5. (continued)

X
URICA-C

M
TAQ-R-P

Y
BPM-P Int

Wa
Atypical

Va
Atypical

URICA-P

TAQ-R-P

BPM-P Int

Ext Dx

Atypical

Expectancies/Motivation Through Adherence to Outcome
CEQ-P
BMQ (M1) BPM-P Att
FIBSER-2

Ua

FIBSER-2

Std.
Indirect
Effectc
0.00
0.73**

Std.
Direct
Effectc
0.29**
0.29**

Std.
Total
Effectc
0.29**
1.02**

Low W, Low V
High W, Low V
Low W, High V
High W, High V

-0.02
0.03
0.29**
-0.50**

0.05
0.05
0.05
0.05

0.03
0.08
0.34**
-0.45**

Low V and U
Med V and U
High V and U

0.15
0.02
-0.12

0.11
-0.47**
-1.05**

0.27
-0.45**
-1.17**

Moderator Levelb
Low V
High V

URICA-C

BMQ (M1) BPM-P Att

FIBSER-2

Low V
Med V
High V

0.17
-0.01
-0.19

-0.44*
-0.44*
-0.44*

-0.27
-0.45
-0.63*

CEQ-P

BMQ (M1) BPM-P Int

Alpha-2

Low V
High V

0.14
-2.55**

-0.31
-0.31

-0.18
-2.86**

URICA-C

BMQ (M1) BPM-P Int

Alpha-2

Low V
High V

0.03
-2.75*

0.47**
0.47**

0.50**
-2.28
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Table 5. (continued)
Std.
Total
Effectc

Va
FIBSER-2

Low W, Low V
High W, Low V
Low W, Med V
High W, Med V
Low W, High V
High W, High V

0.03
-0.43
-0.01
0.10
-0.04
0.63*

0.14
0.14
0.14
0.14
0.14
0.14

0.17
-0.29
0.13
0.24
0.10
0.77*

TAQ-R-C

Alpha-2

Low W, Low V
High W, Low V
Low W, High V
High W, High V

0.01
-0.23
-0.30
6.31*

-0.06
-0.06
-0.06
-0.06

-0.05
-0.29
-0.36
6.24*

Atypical

Moderator Levelb

Std.
Direct
Effectc

Wa
X
M
Y
Alliance Through Adherence to Outcome
TAQ-R-C BMQ (M1) BPM-P Att Atypical

BMQ (M1) BPM-P Int

Ua

Std.
Indirect
Effectc

Note.* p<.05, ** p<.01
Note. M1=1-month follow-up; M3=3-month follow-up; CEQ-C=Credibility/Expectancy Questionnaire-Child Version; URICA-C=
University of Rhode Island Change Assessment-Child Version; URICA-P= University of Rhode Island Change Assessment-Parent
Version; CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; TAQ-R-C=Therapeutic Alliance Quality Rating-Child
Version; TASC-R=Therapeutic Alliance Scale for Children-Revised; WAI-SF=Working Alliance Inventory-Short Form; TAQ-RP=Therapeutic Alliance Quality Rating-Parent Version; BMQ=Brief Medication Questionnaire; Y: BPM-P Att=Brief Progress
Monitor-Parent Version (Attention Problems); BPM-P Ext=Brief Progress Monitor-Parent Version (Externalizing); BPM-P Int=Brief
Progress Monitor-Parent Version (Internalizing); Alpha-2=Alpha-2 agonists; Atypical=Atypical antipsychotic; FIBSER-2=Frequency,
Intensity, and Burden of Side Effects Rating-Item 2 (Intensity); FIBSER-3=Frequency, Intensity, and Burden of Side Effects RatingItem 3 (Interference); CTM1=Concurrent treatment received by 2-month follow-up; CTM3=Concurrent treatment received by 3month follow-up; Ext Dx=Externalizing Diagnosis; Tic Dx=Tic Disorder Diagnosis
a

W reflects moderator of X-M relationship, V reflects moderator of M-Y relationship, and U reflects moderator of c’
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Table 5 (continued.)
b

For continuous moderators, low, medium, high values reflect -1 SD, the mean, and +1 SD respectively for the corresponding
measure. For dichotomous moderators, low values reflect the absence of the moderator (i.e., 0 in dummy-coding), and high values
reflect presence of the moderator (i.e., 1 in dummy-coding).
c

Slopes reflect standardized effects. Significance was evaluated based on unstandardized analyses as recommended by Fairchild and
McQuillin (2010), and standardized results are presented to facilitate interpretation as recommended by Wen and Fan (2015).
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Figure 1. Hypothesized model of psychosocial variables and treatment outcome in pediatric
psychiatry, reflecting all bivariate relationships tested in the present study.
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Figure 2. Graphical depiction of moderated mediation models tested, including the overall
framework (top) and specific 2-mediator model (bottom)
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APPENDIX A:
URICA-P
The following questions address how you view symptoms of depression and anxiety for your
child.

Item

1
Strongly
Disagree

1) As far as I'm concerned, my child
doesn’t have any problems that
need changing.
2) I think my child might be ready for
some improvement.
3) I am doing something about the
problems that had been bothering
my child.
4) It might be worthwhile to work on
my child’s problem.
5) My child isn’t the problem one. It
doesn't make much sense for
him/her to be here.
6) It worries me that my child might
slip back on a problem he/she has
already changed, so I am here to
seek help for him/her.
7) I am finally doing some work on
my child’s problem.
8) I've been thinking that I might want
to change something about my
child.
9) My child has been successful in
working on his/her problem but I'm
not sure I can keep up the help on
my own.
10) At times my child’s problem is
difficult, but I'm working to help.
11) Being here is pretty much a waste
of time because the problem doesn't
have to do with my child.
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2
3
Disagree Undecided

4
Agree

5
Strongly
Agree

12) I'm hoping this place will help me
to better understand my child’s
problem.
13) I guess my child has faults, but
there's nothing that he/she really
needs to change.
14) I am really working hard to help
my child.
15) My child has a problem and I
really think I should work to help.
16) I'm not following through with
helping my child as well as I had
hoped, and I'm here to prevent a
relapse of the problem.
17) Even though I'm not always
successful helping my child, I am
at least working on his/her
problem.
18) I thought once I had resolved my
child’s problem I would be free of
it, but sometimes I still find myself
struggling to help.
19) I wish I had more ideas on how to
solve my child’s problem.
20) I have started working on my
child’s problems but I would like
help.
21) Maybe this place will be able to
help my child.
22) I may need a boost right now to
help me maintain the changes I've
already made in helping my child.
23) I may be able to deal with my
child’s problem better, but I don’t
really think so
24) I hope that someone here will have
some good advice for my child.
25) Anyone can talk about helping
their children; I'm actually doing
something about it.
26) All this talk about psychiatry is
boring. Why can't people just
forget about their problems?
27) I'm here to prevent my child from
having a relapse of his/her
problem.
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28) It is frustrating, but I feel my child
might be having a recurrence of a
problem I thought had been
resolved.
29) I have worries about my child’s
symptoms but so does the next
person. Why spend time thinking
about them?
30) I am actively working on my
child’s problem.
31) I would rather cope with my
child’s faults than try to change
them.
32) After all I had done to try to
change my child’s problem, every
now and again it comes back to
haunt me.
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APPENDIX B:
URICA-C
The following questions address how you view your thoughts and feelings of being down or
nervous.
Item

1
2
3
4
Strongly Disagree Undecided Agree
Disagree

1) As far as I'm concerned, I
don't have any problems that
need changing.
2) I think I might be ready for
some self-improvement.
3) I am doing something about
the problems that had been
bothering me.
4) It might be worthwhile to
work on my problem.
5) I'm not the problem one. It
doesn't make much sense for
me to be here.
6) It worries me that I might slip
back on a problem I have
already changed, so I am here
to seek help.
7) I am finally doing some work
on my problem.
8) I've been thinking that I might
want to change something
about myself.
9) I have been successful in
working on my problem but
I'm not sure I can keep up the
effort on my own.
10) At times my problem is
difficult, but I'm working
on it.
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5
Strongly
Agree

11) Being here is pretty much a
waste of time for me because
the problem doesn't have to do
with me.
12) I'm hoping this place will help
me to better understand
myself.
13) I guess I have faults, but
there's nothing that I really
need to change.
14) I am really working hard to
change.
15) I have a problem and I really
think I should work at it.
16) I'm not following through
with what I had already
changed as well as I had
hoped, and I'm here to prevent
a relapse of the problem.
17) Even though I'm not always
successful in changing, I am
at least working on my
problem.

18) I thought once I had resolved
my problem I would be free of
it, but sometimes I still find
myself struggling with it.
19) I wish I had more ideas on
how to solve the problem.
20) I have started working on my
problems but I would like
help.
21) Maybe this place will be able
to help me.
22) I may need a boost right now
to help me maintain the
changes I've already made.
23) I may be able to deal with my
problem better, but I don’t
really think so.
24) I hope that someone here will
have some good advice for
me.

102

25) Anyone can talk about
changing; I'm actually doing
something about it.
26) All this talk about psychiatry
is boring. Why can't people
just forget about their
problems?
27) I'm here to prevent myself
from having a relapse of my
problem.
28) It is frustrating, but I feel I
might be having a recurrence
of a problem I thought I had
resolved.
29) I have worries but so does the
next person. Why spend time
thinking about them?
30) I am actively working on my
problem.
31) I would rather cope with my
faults than try to change them.
32) After all I had done to try to
change my problem, every
now and again it comes back
to haunt me.
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APPENDIX C:
TAQ-R
All questions below refer to the session that you just completed with this family. Please select
one answer for each question.
Did the youth participate in the session that you just had for him or her?

Yes

No

Did the youth’s caregiver participate in the session that you just had for this youth?

Yes

Very Poor
1.

In this session, how would you
describe your relationship with
this YOUTH?

2.

In this session, how would you
describe your relationship with
this CAREGIVER?

104

No

Poor

Satisfactory

Good

Excellent

APPENDIX D:
WAI-SF
Following are sentences that describe some of the different ways a person might think or feel about his or her family’s counselor. Using the
following 7-point scale, please respond to every item with your first impressions of your counselor:

Never

Rarely

Occasionally

Sometimes

Often

Very Often

Always

1. The counselor and I agree about the things that
my family needs to do in therapy to help
improve our situation.

1

2

3

4

5

6

7

2. What we are doing in counseling gives me new
ways of looking at my family’s problems.

1

2

3

4

5

6

7

3. I believe the counselor likes my family.

1

2

3

4

5

6

7

4. The counselor does not understand what my
family is trying to accomplish in counseling.

1

2

3

4

5

6

7

5. I am confident in the counselor’s ALLIANCE
AND MEDICATION ADHERENCE to
help my family.

1

2

3

4

5

6

7

6. The counselor and my family are working
towards mutually agreed upon goals.

1

2

3

4

5

6

7
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7. I feel that the counselor appreciates my
family.

1

2

3

4

5

6

7

8. We agree on what is important for my family
to work on.

1

2

3

4

5

6

7

9. My family has built a mutual trust with the
counselor.

1

2

3

4

5

6

7

10. My family and the counselor have different
ideas on what our real problems are.

1

2

3

4

5

6

7

11. We have established a good understanding of
the kind of changes that would be good for my
child/family.

1

2

3

4

5

6

7

12. I believe the way we are working with my
family’s problem is correct.

1

2

3

4

5

6

7
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APPENDIX E:
CEQ-P
The following questions address how you believe this treatment will affect your child’s
troublesome symptoms of depression and anxiety.
1. By the end of the therapy period, how much improvement in your child’s problem behavior do
you really feel will occur?
0%

10%

20%

30%

40%

50%

60%

70% 80%

90%

100%

2. By the end of therapy, how much improvement in your child’s behavior do you think will
have occurred?
1
Not at all

2

3

4

5
Somewhat

6

7

8

9
Very much

3. At this point, take a minute to think about how much do you really feel that therapy will help
to reduce your child’s problem behaviors?
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50%

60%
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APPENDIX F:
BMQ
1. Please list below all of the medications your child took in the PAST WEEK. For each
medication you list, please answer each of the questions in the box below.
If he/she has stopped medication completely for these conditions since he/she first saw the
psychiatrist, please write “Stopped” after listing the medication and the reason for stoppage (for
example, side effects).
Medication name
and strength
(if stopped, please
provide the reason)

How many
How many times
days did
per day did
he/she take it?
he/she take it?
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How many
pills did
he/she take
each time?

How many times
did he/she miss
taking a pill?

APPENDIX G:
SACA
In the last 3 months, has your child received outpatient or inpatient help from any of the
following sources?
IF YES:
COL A
NUMBER OF HOURS
OR DAYS OF
SERVICE

1.

2.

3.

4.

Community mental health center or other
outpatient mental health clinic

NO YES DK

__ __ __ hrs.

NO YES DK

__ __ __hrs.

Partial hospitalization or day treatment
program

NO YES DK

__ __ __ hrs.

Drug or alcohol clinic

NO YES DK

Professional like a psychologist,
psychiatrist, social worker, or family
counselor not part of a service or clinic
already mentioned

__ __ __hrs.

5.

6.

Therapist or counselor or family
preservation worker who came to your
home

NO YES DK

Emergency room for problems with
behaviors or feelings
NO YES DK

7.

Pediatrician or family doctor for
problems with behaviors or feelings
NO YES DK
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__ __ __ hrs.

__ __ __hrs.

__ __ __hrs.

IF YES:
CHECK TYPES OF SERVICES
GIVEN:

__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training
__case management
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training
__case management
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training
__case management
__assessment
__individual treatment/therapy
__family/parent treatment/ed
__medication
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training

8.

Probation or juvenile corrections officer
or a court counselor
NO YES DK

9.

10.

11.

Priest, Minister or Rabbi for problems
with behaviors or feelings

__ __ __hrs.

NO YES DK

__ __ __hrs.

NO YES DK

__ __ __hrs.

Acupuncturist/Chiropractor

Crisis hotline

__ __ __hrs.
NO YES DK

12.
13.

Any self-help group like Alcoholics
Anonymous or peer counseling

NO YES DK

Other: describe____________________

NO YES DK

__ __ __hrs.
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____ __ __hrs..

__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__education/training
__assessment
__individual treatment/therapy
__group treatment
__family/parent treatment/ed
__medication
__education/training

APPENDIX H:
FIBSER
INSTRUCTIONS: Select the best response for the following three questions.
1) Choose the response that best describes the frequency (how often) of the side effects of
the medication you have taken within the past week for your depression. Do not rate side
effects if you believe they are due to treatments that you are taking for medical conditions
other than depression or anxiety. Rate the frequency of these side effects for the past
week.
No side
effects

Present
10% of the
time

Present
25% of the
time

Present
50% of the
time

Present
75% of the
time

Present
90% of the
time

Present all
the time

0

1

2

3

4

5

6

2) Choose the response that best describes the intensity (how severe) of the side effects that
you believe are due to the medication you have taken within the last week for your
depression or anxiety. Rate the intensity of the side effect(s), when they occurred, over
the last week.
No side
effects

Trivial

Mild

Moderate

Marked

Severe

Intolerable

0

1

2

3

4

5

6

3) Choose the response that best describes the degree to which antidepressant medication
side effects that you have had over the last week have interfered with your day to day
functions.
No
impairment

Minimal
impairment

Mild
impairment

Moderate
impairment

Marked
impairment

Severe
impairment

Unable to
function
due to
impairment

0

1

2

3

4

5

6
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APPENDIX I:
PRISE
Please indicate all symptoms you have experienced in the past week. These symptoms may or
may not have been caused by your treatment.
1. GASTROINTESTINAL
1.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Diarrhea
Constipation
Dry Mouth
Nausea/vomiting
No symptoms in this category
1.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing
2. HEART
2.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Palpitation (skipping a beat)
Dizziness on standing
Chest pain
No symptoms in this category
2.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing
3. SKIN
3.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Rash
Increased perspiration
Itching
Dry skin
No symptoms in this category

4. NERVOUS SYSTEM
4.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Headache
Tremors
Poor coordination
Dizziness
No symptoms in this category
4.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing
5. EYES/EARS
5.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Blurred Vision
Ringing in ears
No symptoms in this category
5.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing
6. GENITAL/URINARY
6.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Difficulty urinating
Painful Urination
Frequent urination
Menstrual irregularity
No symptoms in this category
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3.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing

6.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing

7. SLEEP
7.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Difficulty sleeping
Sleeping too much
No symptoms in this category
7.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing

8. OTHER
8.1 Check ALL symptoms that you have
experienced during the past week regardless
of cause:
Anxiety
Poor concentration
General malaise
Restlessness
Fatigue
Decreased energy
Other ___________________________
No symptoms in this category
8.2 If you had any symptoms over the last
week, how bad was your WORST symptom?
Tolerable
Distressing
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APPENDIX J:
TASC-R
Please read the sentences below about this meeting you just had with your therapist. After
reading each sentence, decide how much the sentence is like you. There are no right or wrong
answers for this questionnaire, just how you feel.
1. I liked spending time with my therapist.
1
2
3
Not Like Me A Little Like Me
Mostly Like Me

4
Very Much Like Me

2. I found it hard to work with my therapist on solving problems in my life.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
3. I felt like my therapist was on my side and tried to help me.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
4. I worked with my therapist on solving my problems.
1
2
3
Not Like Me A Little Like Me
Mostly Like Me

4
Very Much Like Me

5. When I was with my therapist, I wanted the session to end quickly.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
6. I look forward to meeting with my therapist again.
1
2
3
Not Like Me A Little Like Me
Mostly Like Me

4
Very Much Like Me

7. I felt like my therapist spent too much time working on my problems.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
8. I’d rather have done something other than meet with my therapist.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
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9. I used my time with my therapist to make changes in my life.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
10. I like my therapist.
1
2
Not Like Me A Little Like Me

3
Mostly Like Me

4
Very Much Like Me

11. I would rather have not worked on my problems with my therapist.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
12. I think my therapist and I worked well together on dealing with my problems.
1
2
3
4
Not Like Me A Little Like Me
Mostly Like Me
Very Much Like Me
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APPENDIX K:
CEQ-C
These questions address how you believe this treatment will affect your troublesome thoughts
and feelings of being sad, down, or nervous.

1. By the end of the therapy period, how much improvement in your symptoms do you think will
occur?
0%
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90%

100%

2. At this point, how much do you really feel that therapy will help to reduce your symptoms?
1
Not at all

2

3

4

5
Somewhat

6

7

8

9
Very much

3. By the end of the treatment period, how much improvement do you really feel will occur?
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60%
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APPENDIX L:
Documentation of Institutional Review Board Approval
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